Sensex today | Stock Market Live: Sensex zooms past 1,400 pts, Nifty tops 24,300

SENSEX 78,864.33

+ 1,562.93

NIFTY 24,411.35

+ 450.75

CRUDEOIL 8,250.00

 -114.00

GOLD 144,786.00

+ 1,552.00

SILVER 188,390.00

+ 655.00

SENSEX 78,864.33

+ 1,562.93

NIFTY 24,411.35

+ 450.75

NIFTY 24,411.35

+ 450.75

CRUDEOIL 8,250.00

 -114.00

CRUDEOIL 8,250.00

 -114.00

GOLD 144,786.00

+ 1,552.00

'; } document.getElementById("lgdv").innerHTML = htmlElements; } function numberformat(i) { return Number(parseFloat(i).toFixed(2)).toLocaleString('en', { minimumFractionDigits: 2 }) } async function gatherResponse(response) { const { headers } = response; const contentType = headers.get('content-type') || ''; if (contentType.includes('application/json')) { return await response.json() } return response.text(); } function getWidth() { if (Math.max(document.body.scrollWidth,document.documentElement.scrollWidth,document.body.offsetWidth,document.documentElement.offsetWidth,document.documentElement.clientWidth) > 991) { document.getElementById("mob").style.display = "none"; document.getElementById("lgdv").style.display = "block"; } else { document.getElementById("mob").style.display = "block"; document.getElementById("lgdv").style.display = "none"; } } getWidth(); THIS AD SUPPORTS OUR JOURNALISM. SUBSCRIBE FOR MINIMAL ADS.THIS AD SUPPORTS OUR JOURNALISM. SUBSCRIBE FOR MINIMAL ADS.LIVE

Sensex, Nifty, Share Prices Live: Indian equity benchmarks Sensex and Nifty surged in morning trade on Thursday as a steep fall in crude oil prices following the US midterm election results lifted sentiment

By Team BLKS Badri Narayanan

Updated - November 05, 2026 at 12:07 PM.

ensex Today, Nifty 50 | Stock Market Live Updates: Find here all the live updates related to Sensex, Nifty, BSE, NSE, share prices and Indian stock markets for 5th November 2026.

Benchmark indices opened sharply higher on Thursday, with the Nifty 50 jumping 400 points to 24,360.70 and the Sensex surging 1,418.56 points, or 1.84 per cent, to 78,719.96, as a near 10 per cent crash in crude oil prices and a decisive US midterm election outcome fuelled a broad-based rally across sectors.

As at 11.13 am, Sensex was trading higher by 1427.07 points or 1.85 per cent at 78,728.47, while Nifty was up 408.70 points or 1.71 per cent at 24,369.30.

Follow today’s Q2 results live here

Among Nifty 50 stocks, Shriram Finance led the gainers, rising 6.35 per cent to ₹966.45, followed by IndiGo at ₹5,418.10, up 5.39 per cent. Asian Paints climbed 4.56 per cent to ₹2,528.50, while Tata Motors preferred variant (TMPV) gained 4.13 per cent to ₹290.00. Maruti Suzuki rose 4.06 per cent to ₹12,482, with volume of 1.27 lakh shares changing hands.

On the losing side, Apollo Hospitals fell 2.19 per cent to ₹8,411, the steepest decline among index heavyweights. ONGC dropped 1.85 per cent to ₹230.66, while Cipla slipped 0.56 per cent to ₹1,394.10. Bharti Airtel shed 0.44 per cent to ₹2,058.50 and Coal India edged down 0.35 per cent to ₹398.25.

Nifty 50: Top technical indicators

• Trend: Bullish. The Nifty 50 advance/decline ratio now stands at 40/10, showing a strong bullish bias.
• Immediate support: 24,350 and 24,300. If the contract slips below 24,300, it can fall to 24,280. As long as support at 24,280 holds, the intraday trend will remain bullish.
• Immediate resistance: 24,600 and 24,700. A rally after a likely corrective decline can lift Nifty futures to 24,550.
• Trading strategy: Buy Nifty (Nov) futures at 24,350 with a stop-loss at 24,250. Book profits at 24,550.

• November 5, 2026 12:07

  Sensex trades 1,531.35 pts or 1.98% higher at 78,832.75 by 12.03 pm, and Nifty 50 increases by 443.25 pts or 1.85% to 24,403.85

• November 5, 2026 12:07

  Capacit'e Infraprojects Limited receives Letter of Award (LoA) amounting to ~₹306 crore from Puravankara Limited

  Capacit’e Infraprojects Limited has received a Letter of Award (LOA) for amount of ~₹306 Crore (Rupees Three Hundred Six Crores), excluding GST, from Puravankara Limited.

  The LOA is for the construction of Residential Project comprising of 3 Basements, Ground, 4 Podium, Amenity Level, 25 Residential Floors, Terrace and above Terrace (including Retail Area and Club House) at Estrella Project, Andheri West, Mumbai.

• November 5, 2026 12:06

  Amar K Ambani, Executive Director, YES SECURITIES, on the markets

  “Indian equities are navigating a challenging year, with the Nifty down ~10% year-to-date and staring at the possibility of its first negative calendar-year performance since 2015. While the recent recovery from the 22,200 levels is encouraging, the Nifty remains in a broader consolidation phase, and a return to fresh lifetime highs may be difficult in the near term.

  Having said that, this Samvat presents a hugely attractive opportunity to significantly increase equity exposure. A wide range of stocks are looking extremely oversold, and valuations have become compelling at approximately 17x FY28E and potentially 15x FY29E earnings.

  As investors become more discerning about AI-related valuations and growth expectations, the focus is likely to return to fundamental metrics such as sustainable earnings growth and return on equity. On these parameters, India remains exceptionally well positioned as the fastest-growing large economy. Its underlying growth story remains intact, supported by resilient domestic demand, infrastructure investment and manufacturing expansion.

  There are, however, several structural headwinds that investors must factor in. Elevated global yields, geopolitical uncertainties, crude oil prices, currency pressures, continued FII outflows and the supply overhang from primary market issuances are likely to remain relevant. Even if some tax-related relief for foreign investors materializes, a meaningful and sustained return of FII flows may take time. Global capital will continue to evaluate opportunities in high-yield markets as well as AI and other capital-intensive global themes. Consequently, domestic liquidity is likely to remain an important anchor for Indian equities.

  While we are beginning to see signs of large-cap leadership emerging, broader market participation will be essential for a sustained rally. The coming year is likely to truly be a stock picker’s market, with returns driven increasingly by earnings delivery rather than valuation expansion.

  We expect the Nifty to deliver single-digit return over the next 12 months. However, this near-term consolidation must not be confused with a lack of opportunity. From a 3-5-year investment horizon, the market looks hugely attractive. This is an opportune time for investors to build positions in fundamentally sound businesses that have undergone significant price corrections, while maintaining adequate liquidity to navigate near-term volatility.”

• November 5, 2026 12:02

  LG Electronics India Q2 profit rises 25.7% to ₹489 crore on strong appliance demand

  LG Electronics India Q2 profit rises 25.7% to ₹489 crore

  LG Electronics India Q2 profit rises 25.7% to ₹489 crore, while revenue grows 19.5% to ₹7,380 crore on strong demand for home appliances and air solutions.

• November 5, 2026 12:01

  Goldiam International Limited opens its 29th retail store for lab-grown diamond jewellery in Andhra Pradesh

• November 5, 2026 12:00

  Gold and silver demand ahead of Dhanteras and wedding season by Vikas Gupta – CEO & Strategist at OmniScience Capital

  “In India there are two kinds of demand for gold and silver. One is the inelastic demand which happens on Dhanteras and other festivals, as well as, for the wedding season primarily. There is a certain minimum amount of gold to be bought, depending on the socio-economic and cultural groups, for a wedding. Two is the elastic demand which is related to the price action and speculation as to where the price is going. This demand increases when the expectations of price increases are high. These are usually based on the recent past price action. The Dhanteras volumes are likely to be flat to higher. Wedding season is likely to be slightly higher given that the price of gold had increased significantly and dropped, giving the feel of being able to afford more gold for the same amount of money, anchored to the peak price of gold. Gold as an investment continues being favoured by Indians.”

• November 5, 2026 11:59

  Gold outlook before Dhanteras by Deveya Gaglani, Senior Research Analyst - Commodities, Axis Direct

  Domestic gold prices have corrected by more than 22% from their 2026 peak. This downturn is primarily driven by heightened inflation concerns stemming from a sharp surge in crude oil prices, which has temporarily dampened the appeal of the yellow metal. Geopolitical gridlock is exacerbating this trend; the absence of a US-Iran agreement has injected a significant risk premium into oil markets. Speculation that Donald Trump may resume airstrikes on Iran following the midterm elections continues to apply downward pressure on gold.

  In the short term, gold faces continued downside risk and is expected to consolidate, as it is currently trading below its critical support zone of $3,960. With markets pricing in an anticipated Federal Reserve rate hike in December 2026, we expect further price corrections, potentially driving the metal down to test the $3,700 and $3,600 support levels. Despite these near-term headwinds, current price levels present a highly attractive entry point for long-term investors, particularly those who missed the previous year’s rally. Factoring in the current negative catalysts, the remaining downside risk is limited to approximately 5% to 8%. However, the macroeconomic landscape could shift favorably in the medium term. If a geopolitical peace agreement is reached in the coming months and inflationary pressures are curbed, the Federal Reserve may pivot toward rate cuts—a move that would serve as a powerful long-term catalyst for gold prices.

  Investors are advised to begin accumulating gold in a staggered, systematic manner at these lower valuations. We maintain a long-term bullish outlook with a price target of 165,000 to 180,000 levels by next Dhanteras.

• November 5, 2026 11:53

  Shiprocket posts standalone PAT of Rs 19 crore in Q2FY27, compared to Rs 20.16 crore profit in June 2026 quarter and Rs 8 crore loss in Q2FY26

  Shares traded 5% higher Rs 138.05 on the NSE.

• November 5, 2026 11:48

  Indian aviation could benefit from West Asia conflict de-escalation: Jefferies

  West Asia de-escalation could boost Indian aviation: Jefferies

  Jefferies says easing West Asia tensions could lower fuel and rerouting costs, revive passenger traffic and improve the economics of Indian airlines and airports.

• November 5, 2026 11:41

  Nykaa hits 52-week high at open, then retreats as profit-taking kicks in

  Nykaa hits 52-week high at open, then retreats as profit-taking kicks in

  Shares of FSN E-Commerce Ventures, the parent company of beauty and fashion retailer Nykaa, touched a fresh 52-week high of ₹363.40 at the opening bell on Thursday before reversing sharply to trade at ₹347, down 2.39 per cent or ₹8.50, by mid-morning on the National Stock Exchange

• November 5, 2026 11:29

  Premier Energies denies rumours of a qualified institutional placement (QIP) or block deal, stating that the company has sufficient cash flows

• November 5, 2026 11:29

  LGE India Managing Director Hong Ju Jeon on the company's Q2 performance

  “This performance reflects the broader strength of India’s consumer durables industry, which continues to benefit from rising disposable incomes, growing aspiration for premium products and deepening penetration across metro and emerging markets. As LGE India completes its first year as a listed company, this performance reflects the trust our shareholders have placed in us and our commitment to creating long-term value for them. Moving beyond consumer electronics, we are expanding our footprint in the rapidly evolving B2B sector, by entering a new B2B vertical, Vehicle Solutions.”

• November 5, 2026 11:28

  Markolines Pavement Technologies receives work orders from Brihanmumbai Municipal Corporation (BMC) for road resurfacing works

  Markolines Pavement Technologies informed receipt of work orders from Brihanmumbai Municipal Corporation (BMC) for road resurfacing works using microsurfacing technology on the Eastern Express Highway and Western Express Highway, aggregating to approximately ₹135.20 Crore

  Shares traded 4% lower at Rs 173 on the NSE.

• November 5, 2026 11:27

  LG Electronics India net profit up 25.7 per cent to Rs 489.3 crore revenue up 19.5 per cent to Rs 7380 crore

• November 5, 2026 11:27

  Knowledge Marine & Engineering Works completes acquisition of TSHD River Pearl 48 to support Large-Scale Maintenance Dredging Projects

  Shares down 3% to Rs 3,239.60 on the NSE.

• November 5, 2026 11:13

  Zinc futures approaching a hurdle

  Zinc futures approaching a hurdle 

  Zinc futures (₹418/kg), for more than a week, has been in a consolidation phase. While the trend has not turned bearish yet, the uptrend is now facing a crucial test.

• November 5, 2026 11:00

  Dr. Reddy’s gets marketing authorisation for generic semaglutide injection in Brazil

  Dr. Reddy’s gets marketing authorisation for generic semaglutide injection in Brazil

  Approval expands access for type 2 diabetes treatment; company plans launch with Aché in $244.6 million market

• November 5, 2026 11:00

  Impact of the US elections on the Indian markets by Vinit Bolinjkar – Head of Research – Ventura

  “The Democrats’ sweep of both chambers of Congress could be a near-term positive for Indian equities, as checks on abrupt US policy changes improve risk sentiment. The clearest opportunity is lower oil: Brent’s 8.7% decline on November 4, amid hopes of easing Iran tensions, should support fuel- and crude-linked cost structures at IndiGo, Asian Paints and CEAT, while potentially aiding BPCL and HPCL’s marketing margins. Conversely, sustained lower oil prices could weaken realisations for ONGC and Oil India. Softer US yields and a weaker dollar may also support the rupee and foreign portfolio flows. However, tariffs and immigration restrictions remain partly within presidential authority, so export-oriented textiles and IT services companies such as TCS and Infosys cannot assume immediate relief. Pharmaceutical exporters also face US pricing-policy uncertainty. We favour selective domestic cost beneficiaries over a blanket election-driven rally, with crude prices and policy follow-through the key variables.”

• November 5, 2026 11:00

  Biocon shares up 5%

  Biocon shares traded 5% higher at Rs 362.75 on the NSE.

  Shares down despite a 51 per cent year-on-year decline in profit after tax (PAT) to ₹41 crore in Q2FY27.

• November 5, 2026 11:00

  Commodity Outlook | Ashish Rajodiya, Head of Commodities, PL Capital

  Gold rose about 3% to above $4,040 an ounce on Wednesday and silver gained more than 4% to near $52. The trigger was the Democrats’ win in both chambers of Congress, which pushed the dollar to a one-month low and Treasury yields lower. A divided Congress raises the odds of gridlock and tighter federal spending, which eases the case for heavy government borrowing. Silver moved more than gold because its market is smaller and part of its demand is industrial.

  The rally comes even though the Fed still leans hawkish. Rates were held at 3.75-4.00% last week with two policymakers favouring a hike, and futures put the chance of a December hike near 80%. Unresolved US-Iran tensions continue to support safe-haven demand.

  Gold’s gains now depend on yields staying lower. A rebound in yields or a December hike could take back part of the jump, while a weaker dollar and persistent geopolitical risk would help it hold.

• November 5, 2026 10:39

  Tata Power Renewables Commissions 300 MW Project for SECI in Karnataka

  Shares flat at Rs 361.75 on the NSE.

• November 5, 2026 10:35

  Nifty Prediction Today – November 5, 2026: Nifty futures: Uptrend intact

  Nifty Prediction Today – November 5, 2026: Nifty futures: Uptrend intact 

  Nifty futures show an uptrend with potential dips to 24,350–24,300 before rising to 24,550, amid broad bullish signals and cautious intraday targets.

• November 5, 2026 10:35

  Premier Energies PAT drops 53%, shares fall

  Premier Energies was off the day’s high of Rs 925.70, trading at Rs 890.90 on the NSE at 10.31 am.

  Standalone PAT declined 53% to Rs 35.9 crore in Q2FY27 against Rs 55.1 crore in Q2FY26.

  Board declared interim dividend of Rs 0.50 per share.

  It also too note of Premier Energies Global Environment Private Limited (PEGEPL) to the budget of ₹5,947 crore for the project of setting up of a 10 GW Ingot and Wafer Manufacturing Facility at Naidupeta, Andhra Pradesh by PEGEPL, a wholly owned subsidiary of the Company. The estimated completion timeline for the 5 GW capacity under Phase I is December 31, 2027.

• November 5, 2026 10:34

  PI Industries shares crash 18% after Q2 profit plunges

  PI Industries shares slumped over 18 per cent to hit a fresh 52-week low after the company reported a sharp decline in its standalone net profit for the second quarter of FY27. The stock was trading at ₹1,867.70 on the NSE at 10.25 am, down 14.60 per cent. Read more

• November 5, 2026 10:21

  Rupee falls 9 paise to 94.55 against US dollar in early trade

  Rupee falls 9 paise to 94.55 against US dollar in early trade

  The rupee depreciated 9 paise to 94.55 against the US dollar in early trade on Thursday pressured by the broad strength of the American currency in the overseas market.

• November 5, 2026 10:21

  Lenskart Solutions trades 6.21% higher at Rs 732.50 on the NSE after hitting a 52-week high of Rs 762.75 from Rs 689.70 previous close

  It reported an over two-fold increase in consolidated net profit at Rs 232.45 crore in Q2FY27.

• November 5, 2026 10:20

  BSE shares trade 5% higher at Rs 3,767.80 on the NSE following a 44.9 per cent year-on-year rise in consolidated net profit to ₹809.15 crore for the quarter ended September

• November 5, 2026 10:20

  Mahindra Lifespaces signs its first 100-acre plotted development in MMR; shares up 1% to Rs 318.70 on the NSE

• November 5, 2026 10:20

  Crypto market today: Avinash Shekhar, Co-Founder & CEO, Pi42, writes

  “The cryptocurrency market has witnessed a strong rebound, with Bitcoin gaining nearly 4.7% to trade around $80,500, while Ethereum has outperformed with a 6.9% surge to approximately $2,420. XRP has also participated in the recovery, trading near $1.30. The rally follows heightened volatility surrounding the US midterm elections, with improving market sentiment and short liquidations driving the upward momentum. Nearly $975 million worth of positions were liquidated over the past 24 hours, largely involving traders betting on further declines. Ethereum’s stronger performance reflects renewed buying interest, although the extent of short covering suggests that sustained momentum will depend on fresh capital entering the market.

  Looking ahead, Bitcoin’s ability to consolidate above the $80,000 mark will be crucial in determining the next market direction, while Ethereum’s movement towards $2,500 could indicate further upward momentum. Investors should closely monitor trading volumes, liquidation activity and broader macroeconomic developments to assess the strength of the recovery. Rather than chasing sharp price movements, a disciplined approach with staggered entries, appropriate position sizing and a focus on key support levels would help investors navigate the current market environment. Sustained buying activity across major cryptocurrencies will be an important indicator of whether this rebound can develop into a broader recovery.” 

• November 5, 2026 10:18

  US midterm results and implications: Tanay Dalal, SVP - Business & Economic Research, Axis Bank writes

  “The weaker-than-expected Republican performance in the US midterm elections has renewed debate around the future trajectory of US trade policy and its implications for ongoing trade negotiations with India. While the composition of Congress is unlikely to materially alter the institutional framework governing current trade discussions, the political signal from the election outcome may prove more consequential. Any attempt to restore congressional authority over trade policy would require a veto-proof majority, which remains improbable, while judicial challenges to existing tariff measures continue to face significant uncertainty.

  More importantly, the election results may indicate diminishing political support for tariff-intensive trade policies. Several states that have been disproportionately affected by trade disruptions and tariff-related costs, including Texas, Ohio, Michigan, North Carolina, Kansas and Maine, witnessed a decline in Republican vote share. While tariffs have not materially altered aggregate economic performance, with growth remaining resilient, their costs appear to have been concentrated across specific regions and sectors, increasing their political salience. This aligns with evidence from previous election cycles suggesting that the economic costs of tariffs can influence electoral outcomes at the local level.

  Against the backdrop of a divided government and increasing political constraints on the administration, the scope for pursuing aggressive trade actions may gradually narrow. To the extent that a moderation in tariff policy reduces supply-side frictions and imported cost pressures, it could also contribute to a more favourable inflation outlook and, over time, create greater room for monetary policy easing.

  For India, however, the risk environment remains nuanced. US trade policy is likely to continue reflecting broader geopolitical considerations, particularly with respect to the Ukraine conflict and spillovers of Middle-East dynamics into the Democrat voter base. While the broader direction of travel may be towards reduced tariff activism, India could still remain vulnerable to targeted trade measures where strategic and geopolitical interests intersect.”

• November 5, 2026 10:17

  Democrats take Congress: What it means for markets & the economy -- Ankita Pathak, Head – Global Investments, Ionic Asset writes

  There are many intertwined implications that will become clearer once the oath is taken in January. a) For the tech trade, the surprise Texas win puts the heart of the US data centre buildout under political pressure, so expect more scrutiny on power costs, grid strain and permitting. AI capex continues, but power becomes the bottleneck to own. This is negative tech, the futures fell sharply but then dip buyers came in. A lot of pain in tech has happened a month prior (NDX 100 down 9.8% since Oct-6 highs) so could be in the price b) Gridlock limits new fiscal spending, which is softer for US yields, especially at the long end, but higher inflation for longer could limit yield softening. c) With Netanyahu losing majority, the risk of escalation of US-Iran war could ease, however, that still remains an unknown factor amid possibility of a coalition government in Israel. d) Potentially softer yields and lower geopolitical risk weigh on the DXY, and if that holds, it will likely be positive for gold, EM and commodities. A year after a midterm have historically been good for equities, and we stay constructive, diversified across DMs and EMs and across AI and non AI trades. From here, inflation, yields, the dollar and US-Iran matter more. One big overhang on the market will be behind us after this event and has historically given way to the year-end Santa rally in next 3 months.

• November 5, 2026 10:16

  Sundaram Finance appoints new chairman

  Mr. S. Viji has stepped down as Non-Executive Director and Chairman of the Board, effective November 5, 2026, citing age and personal considerations. The Board has elected Independent Director Mr. R. Venkatraman as the new Chairman of Sundaram Finance.

• November 5, 2026 10:15

  Sundaram Finance shares rise 2% to Rs 4,092 on the NSE

  Company posted standalone PAT of Rs 475.07 crore in Q2FY27 against Rs 521.61 crore in June 2026 quarter and Rs 394.20 crore in Q2FY26.

  Sundaram Finance accorded its approval for the proposed acquisition of 100% stake in Sundaram Alternate Assets limited (SAAL), a wholly-owned subsidiary of Sundaram Asset Management Company Limited (SAMCL), which in turn is a wholly-owned subsidiary of the Company.

• November 5, 2026 10:00

  Dr. Reddy’s receives marketing authorisation for generic semaglutide injection in Brazil; shares flat at Rs 1,372.50 on the NSE

• November 5, 2026 09:59

  Union Bank of India seeks LTCG tax exemption on equity held beyond three years

  Union Bank proposes LTCG tax exemption on equity held beyond three years

  Union Bank seeks lower LTCG tax on equity and a full exemption beyond three years, along with deposit tax cuts to attract foreign capital and boost savings.

• November 5, 2026 09:50

  Crude oil prices fall as US midterm results raise hopes of end to West Asia war

  Crude oil prices fall on hopes of end to West Asia war after US midterms

  Crude oil futures fall as US midterm results raise hopes of an end to the West Asia war, while US crude inventories decline below the five-year average.

• November 5, 2026 09:49

  Fabtech Technologies informs the resignation of Kalpesh Chauhan as Chief Financial Officer of the company w.e.f. November 12, 2026

• November 5, 2026 09:49

  Rajesh Power Services secures order worth ₹1,628.74 crore from Dakshin Gujarat Vij Company Limited (DGVCL)

  Rajesh Power Services secured a landmark turnkey order worth ₹1,628.74 crore from Dakshin Gujarat Vij Company Limited (DGVCL), significantly strengthening its growth trajectory. With this mega order, the Company’s aggregate order book has surged to approximately ₹5,400 crore, representing an impressive ~35% expansion from 4,000 crore prior to this order.

• November 5, 2026 09:48

  Laxmi Dental's 60%-owned jointly controlled entity, Kids-e-Dental LLP, receives EU Quality Management System Certification under MDR 2017/745 and ISO 13485:2016 certification from TÜV SÜD

  Shares up 2% to Rs 192.56 on the NSE.

• November 5, 2026 09:47

  NALCO steadily progressing with its proposed brownfield Smelter Expansion Project at Anugola, Odisha

  National Aluminium Company Limited (NALCO), a Navratna CPSE under the Ministry of Mines, Government of India, is steadily progressing with its proposed brownfield Smelter Expansion Project at Anugola, Odisha, to augment its smelting capacity by 0.5 million tonnes per annum (MTPA), nearly doubling the existing capacity from 0.46 MTPA to approximately 1.0 MTPA.

  Shares flat at Rs 328.50 on the NSE.

• November 5, 2026 09:47

  Crude oil futures trade lower on Thursday morning as a major victory for Democrats in US midterm elections raised hopes of an end to the war in West Asia

  At 9.38 am on Thursday, January Brent oil futures were at $93.96, down by 0.70 per cent, and December crude oil futures on WTI (West Texas Intermediate) were at $86.98, down by 1.29 per cent. November crude oil futures were trading at ₹8234 on Multi Commodity Exchange (MCX) during the initial hour of trading on Thursday against the previous close of ₹8364, down by 1.55 per cent, and December futures were trading at ₹8177 against the previous close of ₹8312, down by 1.62 per cent.

• November 5, 2026 09:44

  Adani Power shares up 1% to Rs 204.07 on the NSE

  Company signed a 25-year Power Supply Agreement (“PSA”) with the Uttarakhand Power Corporation Limited (“UPCL”) for 1,234 MW ex-bus net supply (1,320 MW installed capacity) of Thermal Power pursuant to the Company being declared as the successful bidder in terms of the tender invited and issued by UPCL.

• November 5, 2026 09:43

  Crude crash, US midterm wave send Nifty surging past 24,300

  Crude crash, US midterm wave send Nifty surging past 24,300

  Nifty jumps past 24,300 as crude drop and US midterm results spark broad rally; Sensex soars, FIIs turn buyers.

• November 5, 2026 09:32

  Top movers and declines of Nifty Oil & Gas

  Top movers of Nifty Oil & Gas: HPCL (+6.01%), MGL (+4.10%), BPCL (+4.02%), IOC (+3.08%)

  Declines: OIL (-4.05%), Chennai Petro (-1.86%), ONGC (-1.81%)

• November 5, 2026 09:30

  Nifty 50 top gainers and losers

  Top gainers of Nifty 50: Shriram Finance (+6.04%), IndiGo (+4.85%), Asian Paints (+4.34%), Bajaj Finance (+4.27%), TMPV (+4.31%)

  Top losers: Apollo (-2.90%), ONGC (-1.71%), Dr Reddy’s (-0.79%), Cipla (-0.55%), Max Health (-0.52%)

• November 5, 2026 09:26

  BSE, Lenskart, KSH International, Isgec, Physicswallah, Biocon, Apollo Tyres shares gain after Q2; Nykaa, Cummins India, PI Industries fall

  Follow today’s Q2 results live here

• November 5, 2026 09:20

  Sensex rallies 1,423.00 pts or 1.84% to 78,724.40 at 9.18 am after opening at 78,910.94 compared to 77,301.40 previous close; Nifty 50 zooms 399.25 pts or 1.67% to 24,359.85

• November 5, 2026 09:17

  CoinSwitch on markets today

  BTC crossed $81K as a broader rally across crypto and equity markets followed the US midterm elections. The rally was supported by improving risk sentiment, with investors expecting greater political certainty. BTC’s open interest also rose 1.61%, suggesting fresh market participation. $80K remains as a crucial level for sustaining bullish momentum, with $79K acting as the next support. Holding these levels could set the stage for a potential trend reversal and breakout over the next 7–10 days, said CoinSwitch Markets Desk

• November 5, 2026 09:17

  Mudrex on markets today

  Bitcoin has moved back above $80,000, gaining around 3% after Democrats secured control of both chambers of the US Congress. While the outcome was largely anticipated, the rebound triggered nearly $330 million in short liquidations within an hour, adding to the upward momentum. Historically, Bitcoin has seen post-midterm weakness, with prices falling to cycle lows in the weeks following the 2014, 2018 and 2022 elections before gaining around 25%–90% over the next year. However, uncertainty around the passage of the CLARITY Act over the next two years and $514 million in November ETF outflows continue to weigh on sentiment. Bitcoin needs to break $82,000, with $78,000 as key support, said Prateek Gupta, Head of Business, Mudrex

• November 5, 2026 09:08

  Brokerage updates

  Citi on Apollo Tyres

  Recommendation: Buy, Target: ₹510

  2QFY27 standalone results were above estimates and mitigated impact of a lackluster EU business performance on consolidated earnings.

  In India earnings beat despite weaker gross margin reflected a surprisingly strong revenue growth.

  Margin headwinds in EU business exacerbated the weakness in revenue momentum.

  Would watch out for mgmt commentary on India demand and competitive landscape.

  Watch out for volume and price contribution of revenue growth in India.

  Watch out for raw material and other manufacturing cost trends and 2H outlook.

  Watch out for sustainability of cost optimization undertaken in India.

  Watch out for reasons for weak EU performance.

  Goldman Sachs on Endurance Technologies

  Recommendation: Neutral, Target: ₹2650 (Earlier Target: ₹3090)

  Expects meaningful margin recovery in FY28 as greenfield expansion start up costs moderate.

  Exploring aerospace defence data centres robotics railways solar and power backup opportunities.

  Higher depreciation financing costs and raw material pressures prompt cuts to FY27 to 29 earnings estimates.

  Kotak on Endurance Technologies

  Recommendation: Add, Target: ₹2825 (Earlier Target: ₹3000)

  Stricter safety regulations and expansion into four wheelers and EV components support multi year growth.

  ETL 2.0 strategy targets aerospace defence and other non automotive opportunities.

  European consolidation could drive market share gains but commodity pressures may delay margin recovery.

  Citi on Exide Industries

  Recommendation: Buy, Target: ₹560 (Earlier Target: ₹510)

  Commissioned 6 GWh lithium ion cell gigafactory in Bengaluru with customer qualification and commercial ramp up remaining key triggers.

  Strong automotive OEM wins replacement demand and solar adoption support continued business momentum.

  European battery partnership expands export opportunities while cost optimisation and calibrated pricing support margins.

  HSBC on Tata Motors CV

  Recommendation: Buy, Target: ₹500

  Quality related cost impact resurfaces like 1Q bundled with an adverse product mix leading to EBIT margins near breakeven and affecting cash position.

  Revenue growth decent but weak margins restrict earnings growth as Tata offer sails through and Iveco now a subsidiary.

  Nomura on Tata Motors CV

  Recommendation: Buy, Target: ₹511

  Iveco weak 3Q means TMCV execution to be in focus.

  Demand and margin outlook tougher with catalysts to be internal with significant potential for improvement under TMCV.

  Iveco 3QCY26 industrial margin falls to 0 percent vs 2.8 percent in 2QCY26.

  Citi on Varroc Engineering

  Recommendation: Sell, Target: ₹640

  Recent order wins and Forsee acquisition expected to strengthen revenue growth and expand battery pack business.

  Plans to exit Italian two wheeler lighting facility and shift selected production lines to Vietnam and Romania.

  Margin pressure and rising debt remain concerns with recovery of input cost inflation from OEMs a key monitorable.

  Kotak on Varroc Engineering

  Recommendation: Reduce, Target: ₹740

  EV orders polymer products and overseas expansion to support growth ahead of industry.

  Lighting competition and limited e mobility OEM diversification remain key risks.

  Margin recovery likely to remain subdued amid pricing pressure and slower overseas ramp up.

  Citi on Dabur

  Recommendation: Sell, Target: ₹380

  Revenue EBITDA and recurring PAT grew 12 percent 8 percent and 11 percent YoY.

  Growth construct remained broadly similar to recent quarters with domestic growth driven almost equally by volume and pricing.

  Notably growth was also broad based across segments.

  Mgmt highlighted strengthening performance of the core portfolio premiumisation tailwinds and focused execution as key drivers of performance.

  General trade growth improved to mid to high single digits although we note the benefit of a favourable base following last year GST rate cut implementation.

  Separately company announced a leadership transition and will watch for any shifts in strategic priorities under new CEO.

  HSBC on Dabur

  Recommendation: Hold, Target: ₹426

  Q2FY27 revenue in line and EBITDA 1 to 2 percent below consensus with 5.5 percent volume growth in India FMCG.

  Mohit Malhotra resigns as CEO effective 13 November and Herjit Singh Bhalla will remain India CEO.

  Jefferies on Dabur

  Recommendation: Buy, Target: ₹535 (Earlier Target: ₹610)

  Dabur reported largely steady domestic vols and strong international growth however margin was a miss due to higher opex.

  HPC and foods were strong while healthcare was impacted by ongoing regulatory issues.

  Top mgmt changes across consumer firms continues with Mr Mohit Malhotra resigning.

  Dabur is hosting meet on 5 Nov under Mr Harjit Bhalla so await commentary on strategy and outlook.

  Valuations appear attractive.

  CEO Mohit Malhotra resignation puts upcoming management strategy in focus.

  Rural demand recovery premiumisation and Project Saksham support medium term growth.

  Healthcare faces regulatory challenges causing cuts in earnings estimates by 1 to 4 percent amid cost pressures.

  BofA on Nykaa

  Recommendation: Neutral, Target: ₹400 (Earlier Target: ₹370)

  Beauty growth supported by customer acquisition premiumisation and repeat purchases.

  Nykaa Now and advertising income offer additional growth opportunities.

  Fashion marketing efficiency to improve margins though premium valuations limit rerating.

  HSBC on FSN E Com

  Recommendation: Buy, Target: ₹410

  Robust GMV performance continues with BPC up 25 percent and Fashion up 42 percent while House of brands continues to scale.

  EBITDA margin up 196bp yoy as leverage continues to flow through.

  Raise FY27 EBITDA by 3 percent.

  Jefferies on FSN E Com

  Recommendation: Buy, Target: ₹415 (Earlier Target: ₹400)

  Nykaa delivered a strong 2Q despite the festive shift with EBITDA up 65 percent YoY backed by growth as well multi qtr high margin.

  Beauty sustained healthy momentum and Fashion too delivered strong growth and stayed at breakeven.

  Own brands continued to witness a dream run and Nykaa Now widened its reach and assortment.

  e B2B moderated a bit but will pick up ahead.

  Valuation remains punchy but should be viewed in the context of strong momentum on growth and margins.

  Nomura on FSN E Com

  Recommendation: Buy, Target: ₹427

  Strong growth and margin expansion to continue.

  2QFY27 EBITDA in line with estimates with premiumization and increased brand partnerships to drive growth.

  Expect Nykaa to sustain strong growth momentum with margin expansion driven by premiumization increasing brand partnerships and scale up of own brands.

  Focus on physical expansion in Tier 2 and 3 cities.

  Raise revenue growth estimates by 2 to 4 percent and raise EBITDA margin by 20 to 40bps.

  Citi on Lenskart

  Recommendation: Neutral, Target: ₹700 (Earlier Target: ₹650)

  Store expansion premium lenses and higher volumes support growth.

  Operating leverage and in house manufacturing should drive gradual margin improvement.

  Premium valuations and tougher second half comparisons limit rerating potential.

  CLSA on Lenskart

  Recommendation: Outperform, Target: ₹773

  Sales grew 36 percent YoY in line with estimate.

  Reported Ebitda margin expanded 210bps YoY with Ebitda 3 percent above consensus.

  Delivered another strong quarter especially in India business with robust volume growth and beat on profitability.

  Lenskart ability to profitably serve both ends of the spectrum provides a durable advantage for sustained long term growth.

  HSBC on Lenskart

  Recommendation: Buy, Target: ₹790

  Beat on consensus EBITDA by 3 percent with India SSSG at 21 percent and international sustaining growth at 23 percent constant currency.

  Revise thoughts on India margin expansion and see international as larger opportunity vs earlier.

  India multiple unchanged and international higher.

  Jefferies on Lenskart

  Recommendation: Buy, Target: ₹780 (Earlier Target: ₹680)

  Compounding story continues with strong growth and sharp margin expansion.

  Lenskart is widening the funnel at both ends with Hustlr Club targeting next 100mn Indians evolv elevating experiential retail and smart glasses adding a long term growth vector.

  Despite FX pressure margin progression is on track with seven levers identified toward 25 percent EBITDA without a timeline as growth is a priority.

  Premium valuation is supported by strong growth.

  Macquarie on Lenskart

  Recommendation: Outperform, Target: ₹750

  2Q EBITDA was above estimate as sharper store additions and mix led realisation pickup drove better than expected 50 percent YoY EBITDA growth in India.

  Believe AI led eye testing could widen the customer funnel by increasing testing throughput and reducing optometrist supply constraints.

  Build in stronger ASP assumptions supported by 7 percent growth achieved in 1HFY27.

  Nomura on Lenskart

  Recommendation: Buy, Target: ₹888

  2Q27 above estimates with consolidated sales growth of 32.5 percent.

  EBITDA growth up 65 percent YoY with margin up 270bp YoY to 13.8 percent aided by operating leverage in both India and International.

  India saw strong SSSG and in house manufacturing with rent leverage driving margins.

  International saw volume led growth with pre Ind AS OPM holding up in double digits.

  Key initiatives taken to drive long term volume growth of 20 percent and OPM of 25 percent.

  Jefferies on Emmvee Photovoltaic Power

  Recommendation: Buy, Target: ₹430

  Expects domestic solar module demand of 70 GW in FY27 supported by cheaper renewable power and government schemes.

  Expanding cell capacity to 8.9 GW and module capacity to 16.3 GW with targets of 9 GW ingot wafer integration by FY30.

  Projects 34 percent EBITDA CAGR through FY29 with disciplined order selection aiming to protect margins amid rising competition.

  Jefferies on Torrent Power

  Recommendation: Buy, Target: ₹1635 (Earlier Target: ₹1780)

  Sept Qtr EBITDA was 5 percent above estimates.

  Company has commissioned 310 MW of RE capacity in 1HFY27.

  Management plans to add 1.0 to 1.2 GW in FY27E and 1.4 to 1.6 GW in FY28E vs estimate of 0.6 GW in FY27E and 1.4 GW in FY28E.

  Transmission infra unavailability is leading to delays in commissioning though our estimates already factored delays.

  Expect 13 percent EBITDA CAGR over FY26 to 30E led by 35 percent CAGR in RE EBITDA.

  Citi on Aptus Value Housing Finance

  Recommendation: Buy, Target: ₹285 (Earlier Target: ₹350)

  Cuts FY27 to 29 AUM growth forecasts to 20 to 21 percent amid slower disbursements.

  NBFC asset quality stress and higher funding costs pressure profitability.

  Expects growth recovery by Q4FY27 as management retains above 20 percent ROE guidance.

  Jefferies on Aptus Value Housing Finance

  Recommendation: Buy, Target: ₹290 (Earlier Target: ₹350)

  Expects 20 percent AUM growth in FY27 against management guidance of 22 percent.

  Rising stress in NBFC subsidiary and higher borrowing costs could pressure margins.

  Cuts FY27 to 28 EPS estimates by 1 to 3 percent with attractive valuations and 19 to 20 percent ROE supporting outlook.

  Bernstein on BSE

  Recommendation: Underperform, Target: ₹3180

  Impact from CAS reflected in softer volume growth and market share trends in Q2 results.

  Earnings came ahead of expectations driven by lower SGF contributions during quarter.

  Q3 trends on market volumes and BSE market share gains remain strong.

  Remain concerned about longevity of BSE high growth and consequent normalization of valuations.

  Jefferies on BSE

  Recommendation: Underperform, Target: ₹3100 (Earlier Target: ₹2840)

  Options market share gains may become harder and expects 12 to 15 percent trading volume growth over FY28 to 29.

  Cash equity market share remains below management double digit target.

  Premium valuation versus NSE and management transition by June 2027 remain key concerns.

  JPM on BSE

  Recommendation: Overweight, Target: ₹3960

  Reported revenues of Rs 14.33bn as sharp YoY step up in equity derivatives was impacted by multiple headwinds QoQ.

  EBITDA grew 43 percent YoY to Rs 9.73bn at a 67.9 percent margin.

  Net profit ex CDSL share was Rs 7.83bn aided by a strong Rs 1.18bn other income.

  UBS on BSE

  Recommendation: Outperform, Target: ₹4050

  2Q FY27 saw a beat with cash equities outperforming and normal rate revenue growth accelerating.

  Lower regulatory and operating expenses as a percentage of sales led to the margin beat.

  Macquarie on MCX

  Recommendation: Outperform, Target: ₹3830

  MCX handily beat consensus expectations.

  Are seeing continued acceleration as awareness and acceptance of this niche asset class grows.

  Morgan Stanley on MCX

  Recommendation: Overweight, Target: ₹4055 (Earlier Target: ₹3835)

  Maintains its Overweight rating.

  Revenue forecasts are raised by 4 to 6 percent for FY27 to FY29 driven by higher average daily traded revenue.

  ADTR assumptions have been increased on the back of strong October trading activity.

  Expense estimates are lowered reflecting sufficient core SGF.

  EPS estimates are raised by 5 percent for FY27 and 6 percent for FY28.

  Raises its bull case valuation to 6240 and bear case valuation to 1830.

  Jefferies on Niva Bupa

  Recommendation: Buy, Target: ₹100 (Earlier Target: ₹95)

  Strong retail health growth and market share gains support business expansion.

  Improving claims ratios channel diversification and new products strengthen profitability outlook.

  Hikes FY28 to 29 earnings estimates by 5 to 12 percent with distribution regulations and solvency remaining monitorables.

  Kotak on Samhi Hotels

  Recommendation: Buy, Target: ₹235 (Earlier Target: ₹240)

  Targets 14 to 15 percent same store RevPAR growth in 2HFY27 on strong domestic demand.

  Plans 1669 additional rooms by FY31 and repositioning of 473 rooms into upper upscale segment.

  Expects leverage below 3x by FY27 end with expansion largely funded internally.

  Bernstein IC Abbott India

  Recommendation: Market-Perform, Target: ₹24851

  Strong established brands and commercial execution support steady growth in the domestic pharmaceutical market.

  Limited new molecule pipeline constrains participation in India innovation led healthcare expansion.

  Annual product launches have declined from 11 to five with brand extensions accounting for 80 percent of launches.

  Bernstein IC Pfizer India

  Recommendation: Outperform, Target: ₹4424

  Global innovation pipeline and new specialty medicines expected to transform India growth trajectory.

  Hospital focused therapies and preventive healthcare launches could support double digit revenue growth.

  Improving operating leverage and faster access to globally developed medicines underpin earnings recovery.

  Bernstein IC GSK Pharma India

  Recommendation: Outperform, Target: ₹3430

  Top pick among listed multinational pharma companies supported by a strong global innovation pipeline.

  Adult vaccines specialty respiratory treatments and oncology launches expected to accelerate revenue growth.

  Innovation led portfolio expansion could drive high double digit growth with oncology sales reaching Rs 3.8 bn by FY28.

  Citi on Anthem Biosciences

  Recommendation: Buy, Target: ₹1030 (Earlier Target: ₹870)

  Targets double digit FY27 growth supported by commercial molecule ramp up.

  Unit 4 commissioning targeted around March 2028 with Rs 12 bn planned capex.

  Strong late stage pipeline pharma relationships and efficiency gains support margin outlook.

  Jefferies on Anthem Biosciences

  Recommendation: Buy, Target: ₹1050

  Expects another 1 to 2 late stage molecules to transition to commercial manufacturing over the next 12 months.

  Expanding relationships with global pharmaceutical companies strengthen its CRDMO growth pipeline.

  Plans Rs 12 bn capex including fermentation expansion and new fill and finish capabilities for biologics.

  Citi on Apollo Hosp

  Recommendation: Buy, Target: ₹10770

  Apollo delivered another strong quarter with consolidated revenue EBITDA and PAT growing 23 percent 29 percent and 32 percent YoY.

  Hospitals revenue grew 23 percent driven by 14 percent inpatient volume growth and an 8 percent increase in ARPP.

  EBITDA increased 20 percent despite Rs 348mn of losses and pre operative expenses at new units.

  HealthCo revenue and EBITDA grew 23 percent and 75 percent with the digital business turning cash positive for the first time.

  Strong hospital demand improving HealthCo profitability and the sizeable bed expansion pipeline reinforce confidence in the medium term outlook.

  Potential impact of the oncology trade margin cap and regulatory notice on hospital margins will likely be a key focus area.

  Citi on Aurobindo Pharma

  Recommendation: Sell, Target: ₹1270

  Strong 2QFY27 with EBITDA and PAT beating estimates by 8 percent and 9 percent.

  Driven by robust Europe growth slightly better than expected US traction and currency tailwinds.

  EBITDA margin remained flat QoQ at 21 percent.

  US sales increased 20 percent QoQ to US 477mn largely driven by the Lannett consolidation.

  While continued strength in Europe is encouraging driven by volume growth and market share gains remain cautious about sustainability given market saturation and pricing pressure.

  Following Lannett consolidation expect US growth to stabilize and moderate from the current pace.

  Kotak Inst Eqt on Biocon

  Recommendation: Add, Target: ₹390

  BIOS missed estimates in 2QFY27 due to deferred shipments in biosimilars and lower growth in generics.

  BIOS continues to guide for a strong 2HFY27 largely led by scale up of the recent biosimilar launches.

  Factoring in market share gains new launches and insulin capacity expansion bake in a 15 percent biosimilars sales CAGR over FY2026 to 29E.

  Building in improved growth across segments debt reduction and operating leverage bake in a 17 percent EBITDA CAGR over FY2026 to 29E.

  Following recent stock price correction risk reward has turned favorable even as 1HFY27 execution stayed soft.

  Citi on Dr Lal Pathlabs

  Recommendation: Buy, Target: ₹2380 (Earlier Target: ₹2160)

  Management targets high teens FY27 revenue growth and sustainable mid teens organic growth.

  Network expansion and specialized diagnostics support sustained volume growth.

  Genomics oncology and preventive testing to improve revenue mix and profitability.

  Goldman Sachs on Dr Lal Pathlabs

  Recommendation: Sell, Target: ₹1750 (Earlier Target: ₹1700)

  Management hikes FY27 revenue growth guidance to high teens and EBITDA margin guidance above 28 percent.

  Preventive diagnostics better test mix and higher realisations support earnings growth.

  Hikes FY27 to 29 estimates by up to 4 percent but expensive valuations limit attractiveness.

  Kotak on Dr Lal Pathlabs

  Recommendation: Add, Target: ₹2300

  Hikes FY27 revenue growth guidance to high teens from mid teens.

  Network expansion rural penetration and Suburban turnaround support volume growth.

  Expects 17 percent adjusted EPS CAGR through FY29 aided by specialty diagnostics and genomics.

  Nomura on Dr Lal Pathlabs

  Recommendation: Buy, Target: ₹2280

  Another strong quarter with estimates raised.

  Beat driven by broad based volume growth and realization gains with margins at multi quarter high.

  Model FY27F revenue growth of 18.7 percent and an EBITDA margin of 29.4 percent ahead of management guidance on back of strong 1HFY27 results.

  Jefferies on Lupin

  Recommendation: Underperform, Target: ₹1750 (Earlier Target: ₹2050)

  US sales expected to decline as competition intensifies for Mirabegron and Tolvaptan.

  Key respiratory injectable and biosimilar launches unlikely to contribute meaningfully before FY29.

  Cuts FY27 to 28 EPS estimates by 5 percent and 1 percent and maintains FY27 EBITDA margin guidance of 24 to 25 percent.

  Kotak on Lupin

  Recommendation: Add, Target: ₹2335

  India formulations expected to outperform industry growth by 1.2 to 1.3x.

  US competition in Tolvaptan and Mirabegron to pressure near term profitability.

  Respiratory generics biosimilars and Ellipta launches could drive stronger recovery from FY30.

  Bernstein on Zydus Life

  Recommendation: Buy, Target: ₹1457

  Delivered Q2 revenue of Rs 79.1bn up 29 percent YoY and ahead of both est.

  Believe revenue beat should not be overlooked.

  Disappointment was on costs as EBITDA declined 150 bps more than adjusting for product mix.

  Investments ahead of Saroglitazar launch were higher than estimated.

  Excluding them estimate margin would have been 25.5 percent vs 24 percent reported.

  Reiterate positive view on innovation story and FY28 inflection.

  BofA on Zydus Lifesciences

  Recommendation: Neutral, Target: ₹1200

  gAdempas and gIbrance launches to support US growth in FY28.

  Saroglitazar US launch targeted for March 2027 with meaningful traction expected after FY29.

  US commercialisation spending and elevated R and D costs likely to pressure margins.

  CLSA on Zydus Life

  Recommendation: Outperform, Target: ₹1390

  Reported a revenue growth of 29 percent YoY driven by healthy growth in all segments.

  Margin was in line with its guidance despite continued investments in Saroglitazar launch activities.

  It retained its FY27 guidance of single digit revenue growth in US driven by new launches and India to continue to outpace IPM growth.

  It expects margin of 24 percent plus.

  Zydus continues to invest in building its specialty portfolio and build a differentiated product pipeline.

  Jefferies on Zydus Lifesciences

  Recommendation: Buy, Target: ₹1430 (Earlier Target: ₹1370)

  Saroglitazar awaits US FDA decision in November 2026 with commercial launch targeted for March 2027.

  US specialty portfolio exclusive launches and differentiated Indian products expected to sustain growth.

  Retains North America mid single digit growth guidance and consolidated EBITDA margin guidance above 24 percent.

  Bernstein on US Midterm Elections

  Retains Nifty target at 25000 and sees limited near term gains from Democratic victory.

  Democratic Congress could curb US spending and lower Treasury yields.

  Falling US yields historically supported FII inflows into Indian equities.

  Every 10 bps decline in US yields historically attracted 950 mn in FII inflows.

  Lower yields could strengthen the rupee and improve foreign investor sentiment.

  AI investments and competing emerging markets may limit India foreign inflows.

  US political deadlock could trigger risk aversion and capital outflows.

  Trump tariffs on Russian oil buyers unlikely to change despite Democratic control.

  Middle East tensions and elevated crude prices remain major risks for India.

  H 1B restrictions may face resistance but tighter immigration scrutiny likely to continue.

  Indian IT faces US spending risks with North America contributing over 55 percent of revenues.

  Long term market performance hinges on crude prices external balances and earnings growth.

  BofA on India Equity Strategy

  Democratic sweep raises AI regulation risks and could slow US data centre expansion.

  BofA sees AI capex concerns as overdone with slower investment reducing overcapacity risks.

  US AI capex growing at 26 percent annualised real pace raising overinvestment concerns.

  US growth inflation and Fed forecasts through 2028 remain unchanged.

  State level zoning and permitting restrictions pose bigger risks to AI infrastructure.

  Political gridlock could increase US trade and foreign policy uncertainty.

  India could benefit from lower AI exposure and reduced global technology volatility.

  Lower US yields and weaker dollar could support FII inflows and stabilise INR.

  Korea Taiwan and Japan face greater risks from an AI investment slowdown.

  India limited participation in the AI rally could cushion a global technology correction.

  Indian AI capex exporters trade at expensive 47x forward P E and 1.8x PEG.

  ABB India Siemens and Cummins India face risks from slower US data centre orders.

  Maintain Underweight on AI linked Industrials and Capital Goods exporters.

  Maintain Overweight on Cables given limited US data centre export exposure.

  Prefer Financials Real Estate Autos and Regulated Utilities on potential RBI rate cuts.

  JPMorgan on India Equity Strategy

  Bullish on Indian equities amid falling crude prices lower US yields and renewed FII interest.

  Foreign investors reversing their India underweight could unlock US 115 bn in inflows.

  Lower crude could support the rupee ease inflation and improve corporate margins.

  Expects small and mid caps to outperform large caps on earnings growth.

  Overweight Financials Industrials Healthcare Materials and Consumer Discretionary and Underweight IT.

  Private capex recovery gaining momentum across renewables semiconductors EVs and data centres.

  India peak electricity demand projected to reach 459 GW by FY36 from 271 GW.

  Power transmission investment opportunity estimated at Rs 8 trillion.

  MSCI India trades at a 13.4 percent discount to its 10 year average valuation.

  Banks real estate insurance and materials offer attractive relative valuations.

  Aviation paints cement tyres and logistics among potential beneficiaries of cheaper crude.

  El Nino and weak rainfall threaten rural demand and agricultural incomes.

• November 5, 2026 09:01

  Market review by Vikram Subburaj, CEO, Giottus.com

  Bitcoin is recovering after a volatile stretch. It traded near $80,460 in a November 5 market snapshot, up about 3.94% over 24 hours. The rebound follows a sharp correction and comes as investors digest the US midterm-election outcome and easing ETF redemptions. Immediate support is around 78,000-78,600. A break below could expose 74,400-76,500, followed by $75,000. Resistance is near $80,000, with the 30-day moving average around $81,319. A sustained move above this level would strengthen the recovery. 

  Institutional flows are showing tentative improvement. US spot Bitcoin ETFs recorded $643.2 million in net outflows on October 30, followed by $398.6 million on November 2 and $115.6 million on November 3. The November 4 session then saw a reported $35.1 million inflow. The reversal is modest, but it marks a break in the recent outflow streak. 

  On-chain indicators remain mixed. Bitcoin’s November 4 analysis placed the True Market Mean near $77,700 and the short-term-holder cost basis around $75,700. Only about 38% of short-term holders were in profit, while spot volume remained roughly 1.5 times its pre-rally level. The market has absorbed heavy selling, but this does not yet establish a durable accumulation trend.

  Large-cap altcoins are participating in the rebound. In an Indian-market snapshot at 5:43 a.m. IST, Ethereum traded at Rs.2,29,219, up 6.36%. BNB was at Rs.68,082, up 3.08%. XRP stood at Rs.123, up 2.12%, while Solana traded at Rs.9,030, up 2.83%. TRON was at Rs.30.19, down 0.94%. These are indicative INR market quotes, not synchronized USD prices. 

  Macro signals remain important. The Fed held its target range at 3.75%–4.00% in October. Reuters reported that markets were assigning an 81.2% probability to at least a 25-basis-point December rate hike. US jobless claims and productivity data are due November 5, followed by the October employment report on November 6. Strong labour data could reinforce rate-hike expectations and weigh on risk assets.

  Our advice: Treat the rebound as an early stabilisation attempt, not a confirmed trend reversal. Watch ETF flows, Bitcoin’s 78,00-78,600 support zone and the US labour data before adding risk.

• November 5, 2026 09:00

  Brokerage updates

  Tata Motors CV: HSBC on Tata Motors CV maintains Buy, Target Price Rs 500; Quality-related costs have resurfaced alongside an adverse product mix, pushing EBIT margins close to breakeven and affecting cash flow. Revenue growth remained decent, but weak margins are restricting earnings growth. Tata’s offer has sailed through and Iveco is now a subsidiary.

  Tata Motors CV: Nomura on Tata Motors CV maintains Buy, Target Price Rs 511; Iveco’s weak Q3 performance puts the focus on Tata Motors CV’s execution, with demand and margin conditions becoming more challenging. Nomura sees internal execution as the key catalyst, with significant scope for improvement at Tata Motors CV. Iveco’s industrial margin fell to 0% in 3QCY26 from 2.8% in 2QCY26.

  Dr Lal PathLabs: Nomura on Dr Lal PathLabs maintains Buy, Target Price Rs 2280; Q2FY27 delivered another strong quarter, with broad-based volume growth and improved realisations driving an earnings beat and margins reaching a multi-quarter high. Nomura expects FY27 revenue growth of 18.7% and an EBITDA margin of 29.4%, ahead of management’s 27–28% guidance, supported by strong 1HFY27 performance.

  Torrent Power: Jefferies on Torrent Power maintains Buy, Target Price Rs 1635; September-quarter EBITDA was 5% ahead of estimates, while the company commissioned 310MW of renewable energy capacity in 1HFY27. Management plans to add 1.0–1.2GW in FY27 and 1.4–1.6GW in FY28, above Jefferies’ earlier FY27 estimate. Jefferies expects 13% EBITDA CAGR over FY26–30, led by 35% growth in renewable energy EBITDA, although transmission infrastructure constraints are delaying some commissioning.

  FSN E-Commerce: HSBC on FSN E-Commerce maintains Buy, Target Price raised to Rs 410; GMV growth remained strong, with Beauty and Personal Care growing 25% and Fashion 42%. House of Brands continued to scale, while EBITDA margin expanded around 196bps YoY for the fourth consecutive quarter of 150bps-plus improvement. HSBC raised FY27 EBITDA estimates by around 3%.

  FSN E-Commerce: Nomura on FSN E-Commerce maintains Buy, Target Price Rs 427; Q2FY27 EBITDA was in line with estimates, with premiumisation, increasing brand partnerships and expansion of own brands expected to sustain growth and margin improvement. Expansion into Tier 2 and Tier 3 cities should support the next phase of growth. Nomura raised revenue growth estimates by 2–4% and EBITDA margin estimates by 20–40bps for FY26–28.

  FSN E-Commerce: Jefferies on FSN E-Commerce maintains Buy, Target Price Rs 415; Q2 EBITDA grew 65% YoY, supported by strong growth and multi-quarter-high margins despite the festive-period shift. Beauty maintained healthy momentum, Fashion delivered strong growth at breakeven, and own brands performed well. Nykaa Now expanded its reach and assortment, while e-B2B growth moderated temporarily.

  Lenskart: Nomura on Lenskart maintains Buy, Target Price Rs 888; Q2FY27 sales grew 32.5% YoY, while pre-Ind AS 116 EBITDA rose 65% and margin expanded 270bps to 13.8%, supported by operating leverage in India and international markets. Strong same-store sales growth and in-house manufacturing supported Indian margins, while international growth remained volume-led. Management’s long-term targets include 20% volume growth and 25% operating margin.

  Lenskart: Macquarie on Lenskart maintains Outperform, Target Price Rs 750; Q2 EBITDA exceeded estimates, supported by faster store additions and improved realisations from product mix, driving 50% YoY EBITDA growth in India. Macquarie believes AI-led eye testing could expand the customer funnel by improving testing throughput and easing optometrist supply constraints. Stronger average selling price assumptions are supported by 7% growth in 1HFY27.

  Lenskart: HSBC on Lenskart upgrades to Buy, Target Price raised to Rs 790; Q2 EBITDA beat consensus by 3%, with India same-store sales growth at 21% and international growth at 23% in constant currency. HSBC revised its outlook on Indian margin expansion and sees international markets as a larger growth opportunity than previously expected.

  Lenskart: CLSA on Lenskart maintains Outperform, Target Price Rs 773; Sales grew 36% YoY, or 32.5% on a pro forma basis, while EBITDA margin expanded around 210bps and EBITDA exceeded consensus by 3%. India delivered strong volume growth of 26.5%, with EBITDA 12% ahead of estimates. CLSA sees Lenskart’s ability to serve both value and premium customers profitably as a durable competitive advantage.

  Lenskart: Jefferies on Lenskart maintains Buy, Target Price Rs 780; Strong growth and sharp margin expansion continue to support the company’s compounding story. Hustlr Club, experiential retail format Evolv and smart glasses are expected to widen its customer base and provide additional growth opportunities. Margin progression remains on track towards the 25% EBITDA ambition, although management is prioritising growth without specifying a timeline.

  Dabur: Jefferies on Dabur maintains Buy, Target Price cut to Rs 535; Domestic volumes remained broadly steady and international growth was strong, but margins missed estimates due to higher operating expenses. HPC and Foods performed well, while Healthcare faced regulatory challenges. Jefferies flagged the upcoming leadership transition following CEO Mohit Malhotra’s resignation and awaits management commentary on strategy and outlook.

  Dabur: HSBC on Dabur maintains Hold, Target Price Rs 426; Q2FY27 revenue was in line, while EBITDA came in 1–2% below consensus. India FMCG volume growth stood at 5.5%. CEO Mohit Malhotra will resign effective November 13, with India CEO Herjit Singh Bhalla continuing in his role.

  Dabur: Citi on Dabur maintains Sell, Target Price Rs 380; Q2 revenue, EBITDA and recurring PAT grew 12%, 8% and 11% YoY, respectively, with domestic growth supported almost equally by volumes and pricing or mix. Performance was broad-based across segments, while premium brands now contribute 20% of domestic business. Citi will monitor whether the CEO transition leads to any changes in strategic priorities.

  Biocon: Kotak Institutional Equities on Biocon upgrades to Add, Target Price Rs 390; Q2FY27 missed estimates due to deferred biosimilar shipments and slower generics growth, although management continues to expect a strong second half led by recent biosimilar launches. Kotak expects 15% biosimilars sales CAGR and 17% EBITDA CAGR over FY26–29, supported by market-share gains, new launches, insulin capacity expansion, improved growth and debt reduction. Recent stock price correction has improved the risk-reward.

  Aurobindo Pharma: Citi on Aurobindo Pharma maintains Sell, Target Price Rs 1270; Q2FY27 EBITDA and PAT beat estimates by 8% and 9%, respectively, driven by 19% constant-currency growth in Europe, better-than-expected US traction and currency tailwinds. US sales rose 20% QoQ to US$477mn, largely due to the Lannett consolidation, while EBITDA margin remained flat at 21%. Citi remains cautious about the sustainability of European growth amid market saturation and pricing pressure.

  Zydus Lifesciences: Bernstein on Zydus Lifesciences maintains Buy, Target Price Rs 1457; Q2 revenue grew 29% YoY to Rs 79.1bn, ahead of estimates, although higher-than-expected spending ahead of the Saroglitazar launch weighed on margins. EBITDA margin was 24% against an estimated 25.5% excluding these investments. Bernstein reiterated its positive view on the innovation pipeline and expects an earnings inflection in FY28.

  Zydus Lifesciences: CLSA on Zydus Lifesciences maintains Outperform, Target Price Rs 1390; Q2 revenue grew 29% YoY, driven by healthy performance across segments, while margins remained in line with guidance despite continued investment in the Saroglitazar launch. Management retained its FY27 guidance of single-digit US revenue growth, driven by new launches, and expects India to continue outperforming IPM growth. The company expects margins of 24% or higher.

  Apollo Hospitals: Citi on Apollo Hospitals maintains Buy, Target Price Rs 10770; Q2 consolidated revenue, EBITDA and PAT grew 23%, 29% and 32% YoY, respectively. Hospitals revenue increased 23%, driven by 14% inpatient volume growth and an 8% rise in ARPP, while HealthCo EBITDA grew 75% and its digital business turned cash-positive for the first time. Strong hospital demand, improving HealthCo profitability and the bed-expansion pipeline support the outlook, while oncology trade-margin caps and regulatory notices remain key areas to monitor.

  Apollo Tyres: Citi on Apollo Tyres maintains Buy, Target Price Rs 510; Q2FY27 standalone India results exceeded estimates, offsetting weak performance in the European business. The India earnings beat was supported by stronger-than-expected revenue growth despite weaker gross margins, while European margin pressure compounded revenue weakness. Citi will monitor India demand, competitive intensity, volume and pricing trends, raw-material costs and the sustainability of cost optimisation.

  BSE: UBS on BSE maintains Outperform, Target Price Rs 4050; Q2FY27 results exceeded estimates, with cash equities outperforming and normal-rate revenue growth accelerating. Lower regulatory and operating expenses as a percentage of sales supported the margin beat.

  BSE: Bernstein on BSE maintains Underperform, Target Price raised to Rs 3180; Q2 earnings exceeded expectations, supported by lower contributions to the Settlement Guarantee Fund, while the impact of CAS was reflected in softer volume growth and market-share trends. Bernstein remains concerned about the sustainability of BSE’s high growth as market-share gains peak and valuations normalise.

  BSE: JPMorgan on BSE maintains Overweight, Target Price Rs 3960; Q2 revenue rose 34.1% YoY to Rs 14.33bn, while EBITDA increased 43% YoY to Rs 9.73bn, with margins expanding to 67.9% from 63.7% a year earlier. Net profit excluding CDSL’s contribution rose 45.7% YoY to Rs 7.83bn, supported by higher other income.

  MCX: Macquarie on MCX maintains Outperform, Target Price Rs 3830; Q2 results comfortably exceeded consensus expectations, with business momentum continuing to accelerate as awareness and acceptance of the niche asset class increase.

• November 5, 2026 09:00

  Crypto market analysis for today by Delta Exchange

  “Bitcoin and Ethereum rebounded after the U.S. midterm results eased election uncertainty, while U.S. stocks rallied, oil fell sharply and Treasury yields eased. 

  Bitcoin is near $80,500 after recovering from around $75,600; Ethereum is near $2,426. Both rose above the key EMAs with volume expanding on the move. 

  CoinGlass reported $830.69 million in liquidations affecting 106,231 traders over 24 hours. That forced repositioning likely amplified the rebound.

  Bitcoin ETFs recorded a modest $35.1 million inflow on Nov. 4 after three sessions of heavy outflows, while recent ETF demand remains a concern.

  BTC needs to hold $79,000 and clear $81,700–$82,000; ETH needs to hold $2,397 and break $2,440–$2,450. Continued spot buying and ETF inflows would make the recovery more convincing; otherwise, a pullback toward support remains possible.” - Riya Sehgal, Research Analyst, Delta Exchange

• November 5, 2026 08:51

  Brokerage calls today

  UBS on BSE

  O-P, TP Rs 4050

  2Q FY27 saw a beat, with cash equities outperforming and normal rate revenue growth accelerating.

  Lower regulatory and operating expenses as a percentage of sales led to the margin beat.

  Bernstein on BSE

  U-P TP raised to Rs 3180

  Impact from CAS reflected in softer volume growth and market share trends (both known) in Q2 results

  Earnings came ahead of expectations, driven by lower SGF contributions during quarter.

  Q3 trends on market volumes, & BSE’s market share gains remain strong.

  Remain concerned about longevity of BSE’s high-growth (as market share gains peak), & consequent normalization of valuations

  JPM on BSE

  OW. TP Rs 3960

  Reported revenues of Rs14.33bn (+34.1% YoY/ -8.5% QoQ), as sharp YoY step-up in equity derivatives was impacted by multiple headwinds QoQ.

  EBITDA grew 43%/-7% YoY/QoQ to Rs9.73bn at a 67.9% margin (vs 63.7% a year ago).

  Net profit ex. CDSL’s share was Rs 7.83bn (+45.7% YoY/-8.6% QoQ), aided by a strong Rs1.18bn other income (+65.7% YoY/-16.2% QoQ).

  Macquarie on MCX

  O-P TP Rs 3830

  MCX handily beat consensus expectations.

  Are seeing continued acceleration as awareness and acceptance of this niche asset class grows.

• November 5, 2026 08:50

  News around the world

  USA: Democrats’ sweeping midterm victory increased hopes of an end to the Iran war; Wall Street rallied, while AI data-centre stocks tumbled amid regulatory concerns. Trade deficit narrowed slightly, services growth cooled, and private payrolls improved.

  Japan: Services activity expanded for the fifth consecutive month; BOJ minutes indicated discussions on further interest rate hikes and potentially faster tightening.

  UK: Bank of England is poised for its first interest rate hike in three years; FTSE 100 gained 1%, supported by banks and mining stocks.

  Brazil: Central bank paused its rate-cutting cycle following Lula’s election victory; government reaffirmed its commitment to fiscal discipline.

  Canada: Trade surplus widened to a four-year high of C$5.35 billion, supported by gold and energy exports; services sector contracted for the fifth consecutive month.

  Eurozone: Inflation reached a three-year high, strengthening expectations of an ECB rate hike in December; economic growth slowed to a four-month low.

  Germany: Services sector continued expanding for the second month, but growth slowed amid weak demand and declining new business.

  France: Services sector contracted at its fastest pace since May, with protests and weak domestic demand affecting business activity.

  Italy: Services sector growth accelerated, but inflationary cost pressures intensified due to Middle East tensions.

  Spain: Services sector remained in expansion, although growth slowed and export sales declined.

  India: Services sector growth accelerated to a four-month high in October, supported by stronger domestic demand; hiring remained subdued. 

  Rupee strengthened slightly against the dollar amid falling oil prices.

  China: Services sector growth slowed to a three-month low as weak business confidence, intense competition and rising costs weighed on activity.

  UAE: Non-oil private sector expanded strongly, while businesses increased selling prices at the fastest pace on record due to rising costs.

  Kenya: World Bank raised its 2026 growth forecast following stronger first-half performance but urged the government to tackle corruption.

  Ireland: Tax revenues increased 10.3% during the first ten months of 2026 compared with the previous year.

  New Zealand: Unemployment reached an 11-year high in Q3, adding pressure ahead of national elections.

  Source: Reuters

• November 5, 2026 08:49

  SEBI eases KYC rules for overseas investors, allows digital onboarding without India visit

  SEBI allows overseas investors to complete KYC digitally without visiting India

  SEBI eases KYC rules for NRIs and foreign nationals from FATF-compliant jurisdictions, allowing digital onboarding without visiting India from December 3.

• November 5, 2026 08:35

  Mahanadi Coalfields IPO gets SEBI approval; Coal India to sell 10% stake

  Mahanadi Coalfields IPO gets SEBI approval; key details of Coal India's stake sale

  SEBI approves Mahanadi Coalfields IPO, through which Coal India plans to sell a 10% stake in its subsidiary in one of India's biggest offerings this year.

• November 5, 2026 08:23

  WazirX trade desk report by founder Nischal Shetty (5 November)

  “Bitcoin’s recovery above $80,000 reflects improving risk appetite, although sustained buying will determine whether the rally holds. Bitcoin traded near $80,680, gaining approximately 4.9% over 24 hours, while Ether rose 7.3% to around $2,429. Total crypto market capitalization reached $2.69 trillion, with a trading volume of $94.74 billion. The Fear and Greed Index stood at a neutral 43.

  The recovery coincided with a strong session for US equities. The Dow gained 3.03%, the S&P 500 advanced 1.58% and the Nasdaq climbed 1.44%. The VIX fell more than 20% to 16.61, signalling an easing in demand for protection against market volatility.

  Short covering amplified crypto’s rebound. More than $415 million in liquidations was reported within an hour as Bitcoin reached $80,000, including approximately $330 million in short positions. Separately, the supplied 24-hour snapshot recorded $983.34 million in liquidations. 

  The reported Democratic sweep of Congress brings the pace of US crypto legislation into focus. Bitcoin’s recovery suggests investors absorbed the immediate election uncertainty, although the policy outlook remains a factor for the industry. Futures volume increased 27%, against a 3% rise in open interest.

  Institutional demand remains a watchpoint. Tuesday’s reported outflows of $115.6 million from Bitcoin ETFs and $85.4 million from Ether ETFs indicate that the price recovery has yet to receive consistent support from that channel.

  For Bitcoin, sustaining $80,000 and clearing $82,000 would strengthen the recovery case. The 76,000–78,000 area remains a downside reference zone, followed by $75,000.“

• November 5, 2026 08:15

  KSH International Ltd board approves capacity expansion and capex outlay

  Board approves expansion of Specialized Magnet Winding Wires capacity:

  - Approved capital expenditure of up to INR 185 Cr

  - Expansion for Specialized Magnet Winding Wires at Supa Facility

  - Existing capacity: 57,845 MT

  - Post-expansion capacity: approximately 72,200 MT

  - Target completion: By Q1 FY 2028-29

  - Financing mode: Internal accruals, debt, or a combination thereof

• November 5, 2026 07:35

  Stock to buy today: Usha Martin

• November 5, 2026 07:22

  Trump admits Iran war hurt Republicans in midterm polls but says he would ‘do it again’

  Trump says Iran war cost Republicans midterm election losses but defends decision

  Donald Trump admits the Iran war contributed to Republican midterm losses by raising gasoline prices but insists military action was necessary to stop Iran's nuclear ambitions.

• November 5, 2026 07:22

  India proposes immediate suspension of drug manufacturing licences over quality failures

  India proposes immediate suspension of drug manufacturing licences over quality failures

  India proposes immediate suspension of drug manufacturing licences for medicines failing government quality tests, tightening oversight and strengthening action against drugmakers.

• November 5, 2026 07:21

  US sanctions India-based couple, companies accused of helping Iran’s shadow fleet

  US sanctions Indian couple over alleged role in Iran's shadow fleet

  The US sanctions an India-based couple and associated firms, alleging they helped Iran's shadow fleet transport petroleum using fraudulent maritime registrations.

• November 5, 2026 07:20

  CERT-In flags high-severity security vulnerabilities in Tata Motors’ iRA connected vehicle apps

  CERT-In flags security vulnerabilities in Tata Motors' iRA connected vehicle apps

  CERT-In flags four high-severity vulnerabilities in Tata Motors' iRA apps that could expose user credentials and vehicle data, urging users to update.

• November 5, 2026 07:19

  SEBI cancels registrations of eight investment advisers

  SEBI has cancelled the registrations of eight investment advisers, including Karvy Investment Advisory Services Ltd and IDFC Alternatives Ltd, along with Sagacis Investment Advisor, Tathastu Investment Adviser, Quant Capital, Arkanis Capital, IRA Wealth Advisor, and Indianivesh Investment Managers, for failing to pay the mandatory five-year renewal fees required under the SEBI (Investment Advisers) Regulations, 2013. As a result, their certificates of registration ceased to remain valid, and the cancellations take effect immediately. The regulator noted that the move aims to prevent the misuse of expired certificates that could mislead investors, while clarifying that the entities remain liable for any past activities or obligations from their time as registered advisers.

• November 5, 2026 07:19

  Q2 results on 4 Nov: At a glance

  Lenskart Solutions Ltd. (C)

  Net Revenue at Rs. 2845.0 cr. Vs. Rs. 2096.1 cr. YoY ⬆️, Rs. 2714.2 cr. QoQ ⬆️.

  EBITDA at Rs. 622.0 cr. Vs. Rs. 414.4 cr. YoY ⬆️, Rs. 588.5 cr. QoQ ⬆️.

  EBITDA Margin at 21.9% Vs. 19.8% YoY ⬆️, 21.7% QoQ ⬆️.

  Net Profit at Rs. 232.5 cr. Vs. Rs. 103.5 cr. YoY ⬆️, Rs. 228.4 cr. QoQ ⬆️.

  Zydus Lifesciences Ltd. (C)

  Net Revenue at Rs. 7909.6 cr. Vs. Rs. 6123.2 cr. YoY ⬆️, Rs. 8017.0 cr. QoQ 🔻.

  EBITDA at Rs. 1894.5 cr. Vs. Rs. 2015.8 cr. YoY 🔻, Rs. 1929.4 cr. QoQ 🔻.

  EBITDA Margin at 24.0% Vs. 32.9% YoY 🔻, 24.1% QoQ 🔻.

  Net Profit at Rs. 927.7 cr. Vs. Rs. 1240.9 cr. YoY 🔻, Rs. 990.2 cr. QoQ 🔻.

  Ashika

  Power Finance Corporation Ltd. (C)

  NII at Rs. 10986.7 cr. Vs. Rs. 11576.6 cr. YoY 🔻, Rs. 11276.4 cr. QoQ 🔻.

  Net Profit at Rs. 7681.5 cr. Vs. Rs. 7834.4 cr. YoY 🔻, Rs. 8997.9 cr. QoQ 🔻.

  FSN E-Commerce Ventures Ltd. (C)

  Net Revenue at Rs. 3006.0 cr. Vs. Rs. 2346.0 cr. YoY ⬆️, Rs. 2782.0 cr. QoQ ⬆️.

  EBITDA at Rs. 262.6 cr. Vs. Rs. 159.0 cr. YoY ⬆️, Rs. 236.1 cr. QoQ ⬆️.

  EBITDA Margin at 8.7% Vs. 6.8% YoY ⬆️, 8.5% QoQ ⬆️.

  Net Profit at Rs. 101.2 cr. Vs. Rs. 33.0 cr. YoY ⬆️, Rs. 79.8 cr. QoQ ⬆️.

  Ashika

  Dabur India Ltd. (C)

  Net Revenue at Rs. 3563.1 cr. Vs. Rs. 3191.3 cr. YoY ⬆️, Rs. 3764.4 cr. QoQ 🔻.

  EBITDA at Rs. 632.4 cr. Vs. Rs. 588.1 cr. YoY ⬆️, Rs. 741.4 cr. QoQ 🔻.

  EBITDA Margin at 17.7% Vs. 18.4% YoY 🔻, 19.7% QoQ 🔻.

  Net Profit at Rs. 498.6 cr. Vs. Rs. 444.8 cr. YoY ⬆️, Rs. 586.2 cr. QoQ 🔻.

  Torrent Power Ltd. (C)

  Net Revenue at Rs. 9801.6 cr. Vs. Rs. 7876.0 cr. YoY ⬆️, Rs. 8124.2 cr. QoQ ⬆️.

  EBITDA at Rs. 1738.4 cr. Vs. Rs. 1505.8 cr. YoY ⬆️, Rs. 1537.9 cr. QoQ ⬆️.

  EBITDA Margin at 17.7% Vs. 19.1% YoY 🔻, 18.9% QoQ 🔻.

  Net Profit at Rs. 838.0 cr. Vs. Rs. 741.6 cr. YoY ⬆️, Rs. 661.9 cr. QoQ ⬆️.

  Ashika

  Biocon Ltd. (C)

  Net Revenue at Rs. 4388.9 cr. Vs. Rs. 4295.5 cr. YoY ⬆️, Rs. 4336.0 cr. QoQ ⬆️.

  EBITDA at Rs. 830.9 cr. Vs. Rs. 835.4 cr. YoY 🔻, Rs. 847.2 cr. QoQ 🔻.

  EBITDA Margin at 18.9% Vs. 19.4% YoY 🔻, 19.5% QoQ 🔻.

  Net Profit at Rs. 56.7 cr. Vs. Rs. 132.8 cr. YoY 🔻, Rs. 136.8 cr. QoQ 🔻.

  Physicswallah Ltd. (C)

  Net Revenue at Rs. 1242.3 cr. Vs. Rs. 1051.2 cr. YoY ⬆️, Rs. 1054.0 cr. QoQ ⬆️.

  EBITDA at Rs. 275.9 cr. Vs. Rs. 181.1 cr. YoY ⬆️, Rs. -56.9 cr. QoQ ⬆️.

  EBITDA Margin at 22.2% Vs. 17.2% YoY ⬆️, -5.4% QoQ ⬆️.

  Net Profit at Rs. 143.6 cr. Vs. Rs. 69.7 cr. YoY ⬆️, Rs. -88.3 cr. QoQ ⬆️.

  Ashika

  Exide Industries Ltd. (C)

  Net Revenue at Rs. 5291.9 cr. Vs. Rs. 4364.5 cr. YoY ⬆️, Rs. 5528.4 cr. QoQ 🔻.

  EBITDA at Rs. 561.5 cr. Vs. Rs. 391.4 cr. YoY ⬆️, Rs. 621.5 cr. QoQ 🔻.

  EBITDA Margin at 10.6% Vs. 9.0% YoY ⬆️, 11.2% QoQ 🔻.

  Net Profit at Rs. 287.1 cr. Vs. Rs. 173.6 cr. YoY ⬆️, Rs. 351.3 cr. QoQ 🔻.

  Dr. Lal Pathlabs Ltd. (C)

  Net Revenue at Rs. 873.9 cr. Vs. Rs. 730.6 cr. YoY ⬆️, Rs. 797.7 cr. QoQ ⬆️.

  EBITDA at Rs. 280.2 cr. Vs. Rs. 224.1 cr. YoY ⬆️, Rs. 247.5 cr. QoQ ⬆️.

  EBITDA Margin at 32.1% Vs. 30.7% YoY ⬆️, 31.0% QoQ ⬆️.

  Net Profit at Rs. 193.9 cr. Vs. Rs. 152.2 cr. YoY ⬆️, Rs. 170.5 cr. QoQ ⬆️.

  Ashika

  Kirloskar Oil Engines Ltd. (C)

  Net Revenue at Rs. 2284.0 cr. Vs. Rs. 1948.4 cr. YoY ⬆️, Rs. 1999.5 cr. QoQ ⬆️.

  EBITDA at Rs. 337.5 cr. Vs. Rs. 381.8 cr. YoY 🔻, Rs. 300.3 cr. QoQ ⬆️.

  EBITDA Margin at 14.8% Vs. 19.6% YoY 🔻, 15.0% QoQ 🔻.

  Net Profit at Rs. 130.3 cr. Vs. Rs. 159.2 cr. YoY 🔻, Rs. 111.1 cr. QoQ ⬆️.

  Housing & Urban Development Corporation Ltd. (C)

  NII at Rs. 1183.8 cr. Vs. Rs. 1072.1 cr. YoY ⬆️, Rs. 1156.4 cr. QoQ ⬆️.

  Net Profit at Rs. 911.0 cr. Vs. Rs. 709.8 cr. YoY ⬆️, Rs. 851.1 cr. QoQ ⬆️.

  Ashika

  Redington Ltd. (C)

  Net Revenue at Rs. 42946.9 cr. Vs. Rs. 29075.6 cr. YoY ⬆️, Rs. 34922.5 cr. QoQ ⬆️.

  EBITDA at Rs. 839.0 cr. Vs. Rs. 588.9 cr. YoY ⬆️, Rs. 707.7 cr. QoQ ⬆️.

  EBITDA Margin at 2.0% Vs. 2.0% YoY 🔻, 2.0% QoQ 🔻.

  Net Profit at Rs. 422.5 cr. Vs. Rs. 350.2 cr. YoY ⬆️, Rs. 453.5 cr. QoQ 🔻.

  Apollo Tyres Ltd. (C)

  Net Revenue at Rs. 7968.2 cr. Vs. Rs. 6831.1 cr. YoY ⬆️, Rs. 7397.8 cr. QoQ ⬆️.

  EBITDA at Rs. 855.3 cr. Vs. Rs. 1020.7 cr. YoY 🔻, Rs. 868.0 cr. QoQ 🔻.

  EBITDA Margin at 10.7% Vs. 14.9% YoY 🔻, 11.7% QoQ 🔻.

  Net Profit at Rs. 292.3 cr. Vs. Rs. 258.0 cr. YoY ⬆️, Rs. 348.9 cr. QoQ 🔻.

  Ashika

  Chalet Hotels Ltd. (C)

  Net Revenue at Rs. 502.0 cr. Vs. Rs. 735.3 cr. YoY 🔻, Rs. 512.3 cr. QoQ 🔻.

  EBITDA at Rs. 217.6 cr. Vs. Rs. 299.2 cr. YoY 🔻, Rs. 234.0 cr. QoQ 🔻.

  EBITDA Margin at 43.3% Vs. 40.7% YoY ⬆️, 45.7% QoQ 🔻.

  Net Profit at Rs. 216.3 cr. Vs. Rs. 154.8 cr. YoY ⬆️, Rs. 86.1 cr. QoQ ⬆️.

  Alembic Pharmaceuticals Ltd. (C)

  Net Revenue at Rs. 2603.5 cr. Vs. Rs. 1910.2 cr. YoY ⬆️, Rs. 2149.8 cr. QoQ ⬆️.

  EBITDA at Rs. 563.3 cr. Vs. Rs. 315.7 cr. YoY ⬆️, Rs. 331.9 cr. QoQ ⬆️.

  EBITDA Margin at 21.6% Vs. 16.5% YoY ⬆️, 15.4% QoQ ⬆️.

  Net Profit at Rs. 333.9 cr. Vs. Rs. 183.7 cr. YoY ⬆️, Rs. 172.4 cr. QoQ ⬆️.

  Ashika

  Century Plyboards (India) Ltd. (C)

  Net Revenue at Rs. 1780.0 cr. Vs. Rs. 1385.5 cr. YoY ⬆️, Rs. 1561.4 cr. QoQ ⬆️.

  EBITDA at Rs. 229.7 cr. Vs. Rs. 174.6 cr. YoY ⬆️, Rs. 197.8 cr. QoQ ⬆️.

  EBITDA Margin at 12.9% Vs. 12.6% YoY ⬆️, 12.7% QoQ ⬆️.

  Net Profit at Rs. 103.6 cr. Vs. Rs. 70.9 cr. YoY ⬆️, Rs. 83.3 cr. QoQ ⬆️.

  Marksans Pharma Ltd. (C)

  Net Revenue at Rs. 940.2 cr. Vs. Rs. 720.4 cr. YoY ⬆️, Rs. 840.8 cr. QoQ ⬆️.

  EBITDA at Rs. 214.3 cr. Vs. Rs. 144.5 cr. YoY ⬆️, Rs. 213.0 cr. QoQ ⬆️.

  EBITDA Margin at 22.8% Vs. 20.1% YoY ⬆️, 25.3% QoQ 🔻.

  Net Profit at Rs. 143.5 cr. Vs. Rs. 99.1 cr. YoY ⬆️, Rs. 159.4 cr. QoQ 🔻.

  Ashika

  Thangamayil Jewellery Ltd. (S)

  Net Revenue at Rs. 2387.6 cr. Vs. Rs. 1710.9 cr. YoY ⬆️, Rs. 2666.4 cr. QoQ 🔻.

  EBITDA at Rs. 114.4 cr. Vs. Rs. 105.7 cr. YoY ⬆️, Rs. 144.7 cr. QoQ 🔻.

  EBITDA Margin at 4.8% Vs. 6.2% YoY 🔻, 5.4% QoQ 🔻.

  Net Profit at Rs. 59.5 cr. Vs. Rs. 58.5 cr. YoY ⬆️, Rs. 85.1 cr. QoQ 🔻.

  BASF India Ltd. (C)

  Net Revenue at Rs. 4832.2 cr. Vs. Rs. 3895.8 cr. YoY ⬆️, Rs. 4824.3 cr. QoQ ⬆️.

  EBITDA at Rs. 91.5 cr. Vs. Rs. 154.8 cr. YoY 🔻, Rs. 504.4 cr. QoQ 🔻.

  EBITDA Margin at 1.9% Vs. 4.0% YoY 🔻, 10.5% QoQ 🔻.

  Net Profit at Rs. 61.7 cr. Vs. Rs. 100.6 cr. YoY 🔻, Rs. 347.8 cr. QoQ 🔻.

  Ashika

  Balrampur Chini Mills Ltd. (C)

  Net Revenue at Rs. 1876.3 cr. Vs. Rs. 1670.8 cr. YoY ⬆️, Rs. 1636.8 cr. QoQ ⬆️.

  EBITDA at Rs. 171.4 cr. Vs. Rs. 120.4 cr. YoY ⬆️, Rs. 113.9 cr. QoQ ⬆️.

  EBITDA Margin at 9.1% Vs. 7.2% YoY ⬆️, 7.0% QoQ ⬆️.

  Net Profit at Rs. 102.3 cr. Vs. Rs. 53.9 cr. YoY ⬆️, Rs. 44.1 cr. QoQ ⬆️.

  JSW Dulux Ltd. (C)

  Net Revenue at Rs. 961.9 cr. Vs. Rs. 827.6 cr. YoY ⬆️, Rs. 965.0 cr. QoQ 🔻.

  EBITDA at Rs. 111.0 cr. Vs. Rs. 110.7 cr. YoY ⬆️, Rs. 115.1 cr. QoQ 🔻.

  EBITDA Margin at 11.5% Vs. 13.4% YoY 🔻, 11.9% QoQ 🔻.

  Net Profit at Rs. 71.4 cr. Vs. Rs. 1682.8 cr. YoY 🔻, Rs. 79.7 cr. QoQ 🔻.

  Ashika

  Varroc Engineering Ltd. (C)

  Net Revenue at Rs. 2947.9 cr. Vs. Rs. 2207.3 cr. YoY ⬆️, Rs. 2634.2 cr. QoQ ⬆️.

  EBITDA at Rs. 257.1 cr. Vs. Rs. 203.0 cr. YoY ⬆️, Rs. 221.9 cr. QoQ ⬆️.

  EBITDA Margin at 8.7% Vs. 9.2% YoY 🔻, 8.4% QoQ ⬆️.

  Net Profit at Rs. 33.5 cr. Vs. Rs. 63.3 cr. YoY 🔻, Rs. 77.7 cr. QoQ 🔻.

  Aptus Value Housing Finance India Ltd. (c)

  NII at Rs. 463.2 cr. Vs. Rs. 379.0 cr. YoY ⬆️, Rs. 430.6 cr. QoQ ⬆️.

  Net Profit at Rs. 267.4 cr. Vs. Rs. 226.5 cr. YoY ⬆️, Rs. 260.9 cr. QoQ ⬆️.

  Ashika

  Ircon International Ltd. (C)

  Net Revenue at Rs. 2271.7 cr. Vs. Rs. 1976.8 cr. YoY ⬆️, Rs. 1955.8 cr. QoQ ⬆️.

  EBITDA at Rs. 238.6 cr. Vs. Rs. 141.2 cr. YoY ⬆️, Rs. 205.1 cr. QoQ ⬆️.

  EBITDA Margin at 10.5% Vs. 7.1% YoY ⬆️, 10.5% QoQ ⬆️.

  Net Profit at Rs. 100.3 cr. Vs. Rs. 136.5 cr. YoY 🔻, Rs. 92.0 cr. QoQ ⬆️.

  Rites Ltd. (C)

  Net Revenue at Rs. 556.8 cr. Vs. Rs. 548.7 cr. YoY ⬆️, Rs. 532.2 cr. QoQ ⬆️.

  EBITDA at Rs. 122.1 cr. Vs. Rs. 129.6 cr. YoY 🔻, Rs. 114.7 cr. QoQ ⬆️.

  EBITDA Margin at 21.9% Vs. 23.6% YoY 🔻, 21.5% QoQ ⬆️.

  Net Profit at Rs. 97.1 cr. Vs. Rs. 109.1 cr. YoY 🔻, Rs. 97.8 cr. QoQ 🔻.

  Ashika

  Saregama India Ltd. (C)

  Net Revenue at Rs. 314.3 cr. Vs. Rs. 230.0 cr. YoY ⬆️, Rs. 263.6 cr. QoQ ⬆️.

  EBITDA at Rs. 102.0 cr. Vs. Rs. 68.8 cr. YoY ⬆️, Rs. 93.3 cr. QoQ ⬆️.

  EBITDA Margin at 32.4% Vs. 29.9% YoY ⬆️, 35.4% QoQ 🔻.

  Net Profit at Rs. 64.2 cr. Vs. Rs. 43.8 cr. YoY ⬆️, Rs. 51.9 cr. QoQ ⬆️.

  Indo Count Industries Ltd. (C)

  Net Revenue at Rs. 1672.7 cr. Vs. Rs. 1062.1 cr. YoY ⬆️, Rs. 1207.0 cr. QoQ ⬆️.

  EBITDA at Rs. 233.0 cr. Vs. Rs. 103.7 cr. YoY ⬆️, Rs. 143.4 cr. QoQ ⬆️.

  EBITDA Margin at 13.9% Vs. 9.8% YoY ⬆️, 11.9% QoQ ⬆️.

  Net Profit at Rs. 131.9 cr. Vs. Rs. 39.0 cr. YoY ⬆️, Rs. 63.2 cr. QoQ ⬆️.

  Ashika

  Jyothy Labs Ltd. (S)

  Net Revenue at Rs. 760.0 cr. Vs. Rs. 736.1 cr. YoY ⬆️, Rs. 773.4 cr. QoQ 🔻.

  EBITDA at Rs. 19.2 cr. Vs. Rs. 118.3 cr. YoY 🔻, Rs. 64.7 cr. QoQ 🔻.

  EBITDA Margin at 2.5% Vs. 16.1% YoY 🔻, 8.4% QoQ 🔻.

  Net Profit at Rs. 10.6 cr. Vs. Rs. 87.8 cr. YoY 🔻, Rs. 47.6 cr. QoQ 🔻.

  ISGEC Heavy Engineering Ltd. (C)

  Net Revenue at Rs. 1850.4 cr. Vs. Rs. 1661.8 cr. YoY ⬆️, Rs. 1980.0 cr. QoQ 🔻.

  EBITDA at Rs. 147.4 cr. Vs. Rs. 106.7 cr. YoY ⬆️, Rs. 123.6 cr. QoQ ⬆️.

  EBITDA Margin at 8.0% Vs. 6.4% YoY ⬆️, 6.2% QoQ ⬆️.

  Net Profit at Rs. 66.2 cr. Vs. Rs. 12.6 cr. YoY ⬆️, Rs. 17.5 cr. QoQ ⬆️.

  Ashika

  SJS Enterprises Ltd. (C)

  Net Revenue at Rs. 282.7 cr. Vs. Rs. 241.8 cr. YoY ⬆️, Rs. 261.0 cr. QoQ ⬆️.

  EBITDA at Rs. 83.4 cr. Vs. Rs. 68.4 cr. YoY ⬆️, Rs. 74.7 cr. QoQ ⬆️.

  EBITDA Margin at 29.5% Vs. 28.3% YoY ⬆️, 28.6% QoQ ⬆️.

  Net Profit at Rs. 58.3 cr. Vs. Rs. 43.3 cr. YoY ⬆️, Rs. 74.4 cr. QoQ 🔻.

  Cera Sanitaryware Ltd. (S)

  Net Revenue at Rs. 603.0 cr. Vs. Rs. 473.4 cr. YoY ⬆️, Rs. 486.0 cr. QoQ ⬆️.

  EBITDA at Rs. 73.3 cr. Vs. Rs. 67.1 cr. YoY ⬆️, Rs. 49.2 cr. QoQ ⬆️.

  EBITDA Margin at 12.2% Vs. 14.2% YoY 🔻, 10.1% QoQ ⬆️.

  Net Profit at Rs. 56.1 cr. Vs. Rs. 56.6 cr. YoY 🔻, Rs. 45.3 cr. QoQ ⬆️.

  Ashika

  Mrs. Bectors Food Specialities Ltd. (C)

  Net Revenue at Rs. 630.5 cr. Vs. Rs. 551.4 cr. YoY ⬆️, Rs. 548.7 cr. QoQ ⬆️.

  EBITDA at Rs. 82.5 cr. Vs. Rs. 69.3 cr. YoY ⬆️, Rs. 72.1 cr. QoQ ⬆️.

  EBITDA Margin at 13.1% Vs. 12.6% YoY ⬆️, 13.1% QoQ 🔻.

  Net Profit at Rs. 45.7 cr. Vs. Rs. 36.5 cr. YoY ⬆️, Rs. 38.8 cr. QoQ ⬆️.

  Redtape Ltd. (C)

  Net Revenue at Rs. 474.8 cr. Vs. Rs. 492.4 cr. YoY 🔻, Rs. 481.3 cr. QoQ 🔻.

  EBITDA at Rs. 74.8 cr. Vs. Rs. 46.3 cr. YoY ⬆️, Rs. 83.5 cr. QoQ 🔻.

  EBITDA Margin at 15.8% Vs. 9.4% YoY ⬆️, 17.4% QoQ 🔻.

  Net Profit at Rs. 34.9 cr. Vs. Rs. 27.5 cr. YoY ⬆️, Rs. 44.5 cr. QoQ 🔻.

  Ashika

  Shivalik Bimetal Controls Ltd. (C)

  Net Revenue at Rs. 197.8 cr. Vs. Rs. 137.4 cr. YoY ⬆️, Rs. 182.2 cr. QoQ ⬆️.

  EBITDA at Rs. 50.2 cr. Vs. Rs. 31.1 cr. YoY ⬆️, Rs. 43.2 cr. QoQ ⬆️.

  EBITDA Margin at 25.4% Vs. 22.6% YoY ⬆️, 23.7% QoQ ⬆️.

  Net Profit at Rs. 34.8 cr. Vs. Rs. 24.9 cr. YoY ⬆️, Rs. 33.0 cr. QoQ ⬆️.

  CE Info Systems Ltd. (C)

  Net Revenue at Rs. 131.7 cr. Vs. Rs. 113.8 cr. YoY ⬆️, Rs. 139.7 cr. QoQ 🔻.

  EBITDA at Rs. 45.0 cr. Vs. Rs. 28.1 cr. YoY ⬆️, Rs. 56.1 cr. QoQ 🔻.

  EBITDA Margin at 34.1% Vs. 24.7% YoY ⬆️, 40.2% QoQ 🔻.

  Net Profit at Rs. 35.3 cr. Vs. Rs. 18.5 cr. YoY ⬆️, Rs. 49.7 cr. QoQ 🔻.

  Ashika

  Keystone Realtors Ltd (C)

  Net Revenue at Rs. 496.7 cr. Vs. Rs. 499.3 cr. YoY 🔻, Rs. 470.3 cr. QoQ ⬆️.

  EBITDA at Rs. 57.8 cr. Vs. Rs. 15.4 cr. YoY ⬆️, Rs. 82.2 cr. QoQ 🔻.

  EBITDA Margin at 11.6% Vs. 3.1% YoY ⬆️, 17.5% QoQ 🔻.

  Net Profit at Rs. 100.8 cr. Vs. Rs. 9.9 cr. YoY ⬆️, Rs. 52.4 cr. QoQ ⬆️.

  Unichem Laboratories Ltd. (C)

  Net Revenue at Rs. 640.2 cr. Vs. Rs. 579.0 cr. YoY ⬆️, Rs. 632.6 cr. QoQ ⬆️.

  EBITDA at Rs. 74.5 cr. Vs. Rs. 66.2 cr. YoY ⬆️, Rs. 69.9 cr. QoQ ⬆️.

  EBITDA Margin at 11.6% Vs. 11.4% YoY ⬆️, 11.1% QoQ ⬆️.

  Net Profit at Rs. 22.2 cr. Vs. Rs. -11.9 cr. YoY ⬆️, Rs. 41.5 cr. QoQ 🔻.

  Ashika

  Sangam (India) Ltd. (C)

  Net Revenue at Rs. 1045.3 cr. Vs. Rs. 786.2 cr. YoY ⬆️, Rs. 860.4 cr. QoQ ⬆️.

  EBITDA at Rs. 121.2 cr. Vs. Rs. 76.9 cr. YoY ⬆️, Rs. 105.4 cr. QoQ ⬆️.

  EBITDA Margin at 11.6% Vs. 9.8% YoY ⬆️, 12.2% QoQ 🔻.

  Net Profit at Rs. 53.4 cr. Vs. Rs. 23.1 cr. YoY ⬆️, Rs. 41.0 cr. QoQ ⬆️.

  JTEKT India Ltd. (S)

  Net Revenue at Rs. 834.7 cr. Vs. Rs. 639.1 cr. YoY ⬆️, Rs. 718.0 cr. QoQ ⬆️.

  EBITDA at Rs. 58.1 cr. Vs. Rs. 46.3 cr. YoY ⬆️, Rs. 38.2 cr. QoQ ⬆️.

  EBITDA Margin at 7.0% Vs. 7.2% YoY 🔻, 5.3% QoQ ⬆️.

  Net Profit at Rs. 17.5 cr. Vs. Rs. 18.2 cr. YoY 🔻, Rs. 6.2 cr. QoQ ⬆️.

  Ashika

  Carysil Ltd. (C)

  Net Revenue at Rs. 275.7 cr. Vs. Rs. 240.7 cr. YoY ⬆️, Rs. 262.1 cr. QoQ ⬆️.

  EBITDA at Rs. 51.8 cr. Vs. Rs. 46.1 cr. YoY ⬆️, Rs. 53.4 cr. QoQ 🔻.

  EBITDA Margin at 18.8% Vs. 19.2% YoY 🔻, 20.4% QoQ 🔻.

  Net Profit at Rs. 29.0 cr. Vs. Rs. 27.4 cr. YoY ⬆️, Rs. 32.1 cr. QoQ 🔻.

  Panama Petrochem Ltd. (C)

  Net Revenue at Rs. 1722.3 cr. Vs. Rs. 773.2 cr. YoY ⬆️, Rs. 1735.2 cr. QoQ 🔻.

  EBITDA at Rs. 295.7 cr. Vs. Rs. 68.7 cr. YoY ⬆️, Rs. 387.9 cr. QoQ 🔻.

  EBITDA Margin at 17.2% Vs. 8.9% YoY ⬆️, 22.4% QoQ 🔻.

  Net Profit at Rs. 243.3 cr. Vs. Rs. 53.0 cr. YoY ⬆️, Rs. 308.9 cr. QoQ 🔻.

  Ashika

  Stove Kraft Ltd. (S)

  Net Revenue at Rs. 584.7 cr. Vs. Rs. 474.4 cr. YoY ⬆️, Rs. 480.6 cr. QoQ ⬆️.

  EBITDA at Rs. 75.6 cr. Vs. Rs. 56.8 cr. YoY ⬆️, Rs. 53.8 cr. QoQ ⬆️.

  EBITDA Margin at 12.9% Vs. 12.0% YoY ⬆️, 11.2% QoQ ⬆️.

  Net Profit at Rs. 29.2 cr. Vs. Rs. 21.4 cr. YoY ⬆️, Rs. 17.1 cr. QoQ ⬆️.

  Vintage Coffee & Beverages Ltd. (S)

  Net Revenue at Rs. 223.0 cr. Vs. Rs. 135.6 cr. YoY ⬆️, Rs. 55.5 cr. QoQ ⬆️.

  EBITDA at Rs. 42.2 cr. Vs. Rs. 22.3 cr. YoY ⬆️, Rs. -0.5 cr. QoQ ⬆️.

  EBITDA Margin at 18.9% Vs. 16.5% YoY ⬆️, -0.9% QoQ ⬆️.

  Net Profit at Rs. 28.1 cr. Vs. Rs. 17.8 cr. YoY ⬆️, Rs. 2.7 cr. QoQ ⬆️.

  Ashika

  Sundaram-Clayton Ltd. (C)

  Net Revenue at Rs. 697.7 cr. Vs. Rs. 494.8 cr. YoY ⬆️, Rs. 591.7 cr. QoQ ⬆️.

  EBITDA at Rs. 32.3 cr. Vs. Rs. 14.8 cr. YoY ⬆️, Rs. 11.9 cr. QoQ ⬆️.

  EBITDA Margin at 4.6% Vs. 3.0% YoY ⬆️, 2.0% QoQ ⬆️.

  Net Profit at Rs. -50.8 cr. Vs. Rs. -64.4 cr. YoY ⬆️, Rs. -59.3 cr. QoQ ⬆️.

  Gaja Alternative Asset Management Ltd. (C)

  Net Revenue at Rs. 38.4 cr. Vs. Rs. 68.5 cr. YoY 🔻, Rs. 15.6 cr. QoQ ⬆️.

  EBITDA at Rs. 26.1 cr. Vs. Rs. 46.2 cr. YoY 🔻, Rs. -2.1 cr. QoQ ⬆️.

  EBITDA Margin at 68.0% Vs. 67.4% YoY ⬆️, -13.2% QoQ ⬆️.

  Net Profit at Rs. 64.7 cr. Vs. Rs. 42.0 cr. YoY ⬆️, Rs. 27.2 cr. QoQ ⬆️.

  Arman Financial Services Ltd. (C)

  Net Revenue at Rs. 234.6 cr. Vs. Rs. 159.2 cr. YoY ⬆️, Rs. 201.8 cr. QoQ ⬆️.

  EBITDA at Rs. 143.0 cr. Vs. Rs. 68.0 cr. YoY ⬆️, Rs. 121.9 cr. QoQ ⬆️.

  EBITDA Margin at 60.9% Vs. 42.7% YoY ⬆️, 60.4% QoQ ⬆️.

  Net Profit at Rs. 51.5 cr. Vs. Rs. 8.0 cr. YoY ⬆️, Rs. 45.2 cr. QoQ ⬆️.

  Ashika

  Diffusion Engineers Ltd. (C)

  Net Revenue at Rs. 125.9 cr. Vs. Rs. 83.6 cr. YoY ⬆️, Rs. 110.1 cr. QoQ ⬆️.

  EBITDA at Rs. 16.6 cr. Vs. Rs. 12.4 cr. YoY ⬆️, Rs. 14.2 cr. QoQ ⬆️.

  EBITDA Margin at 13.2% Vs. 14.8% YoY 🔻, 12.9% QoQ ⬆️.

  Net Profit at Rs. 12.8 cr. Vs. Rs. 10.2 cr. YoY ⬆️, Rs. 16.7 cr. QoQ 🔻.

  NDR Auto Components Ltd. (C)

  Net Revenue at Rs. 244.0 cr. Vs. Rs. 200.0 cr. YoY ⬆️, Rs. 221.5 cr. QoQ ⬆️.

  EBITDA at Rs. 23.6 cr. Vs. Rs. 21.8 cr. YoY ⬆️, Rs. 25.3 cr. QoQ 🔻.

  EBITDA Margin at 9.7% Vs. 10.9% YoY 🔻, 11.4% QoQ 🔻.

  Net Profit at Rs. 19.8 cr. Vs. Rs. 14.8 cr. YoY ⬆️, Rs. 16.4 cr. QoQ ⬆️.

  Ashika

  Creative Newtech Ltd. (C)

  Net Revenue at Rs. 752.5 cr. Vs. Rs. 655.8 cr. YoY ⬆️, Rs. 476.1 cr. QoQ ⬆️.

  EBITDA at Rs. 37.9 cr. Vs. Rs. 22.9 cr. YoY ⬆️, Rs. 24.2 cr. QoQ ⬆️.

  EBITDA Margin at 5.0% Vs. 3.5% YoY ⬆️, 5.1% QoQ 🔻.

  Net Profit at Rs. 25.9 cr. Vs. Rs. 18.9 cr. YoY ⬆️, Rs. 13.5 cr. QoQ ⬆️.

  Garuda Construction & Engineering Ltd. (C)

  Net Revenue at Rs. 171.6 cr. Vs. Rs. 116.5 cr. YoY ⬆️, Rs. 175.4 cr. QoQ 🔻.

  EBITDA at Rs. 54.0 cr. Vs. Rs. 34.4 cr. YoY ⬆️, Rs. 56.1 cr. QoQ 🔻.

  EBITDA Margin at 31.5% Vs. 29.5% YoY ⬆️, 32.0% QoQ 🔻.

  Net Profit at Rs. 40.6 cr. Vs. Rs. 27.1 cr. YoY ⬆️, Rs. 41.5 cr. QoQ 🔻.

  Ashika

  GPT Infraprojects Ltd. (C)

  Net Revenue at Rs. 291.4 cr. Vs. Rs. 278.7 cr. YoY ⬆️, Rs. 302.1 cr. QoQ 🔻.

  EBITDA at Rs. 41.3 cr. Vs. Rs. 39.5 cr. YoY ⬆️, Rs. 47.5 cr. QoQ 🔻.

  EBITDA Margin at 14.2% Vs. 14.2% YoY 🔻, 15.7% QoQ 🔻.

  Net Profit at Rs. 17.6 cr. Vs. Rs. 21.5 cr. YoY 🔻, Rs. 24.3 cr. QoQ 🔻.

• November 5, 2026 07:16

  Institutional flow (4th Nov, 2026)

  FIIs: +7,284 Crs 

  DIIs: -3,712 Crs

  Net: 3,572 Cr

• November 5, 2026 07:15

  All-time high breakout alert: 12 stocks broke above their previous all-time highs and closed at record levels on November 4

  ❇️Bosch 

  ❇️Marico 

  ❇️Adani Ports 

  ❇️Ather Energy 

  ❇️Welspun Living 

  ❇️Krishna Phoschem 

  ❇️CORONA Remedies 

  ❇️Nazara Technologies 

  ❇️Indo Count Industries 

  ❇️SMS Pharmaceuticals 

  ❇️Emcure Pharmaceuticals 

  ❇️Spectrum Electrical Industries 

• November 5, 2026 07:15

  Major Q2 results out now

  POWER FINANCE 2Q NET INCOME 49.9B RUPEES, EST. 46.96B RUPEES

  HUDCO Q2 FY27

  * Net Profit: ₹911 Cr ↑28% YoY | ↑7% QoQ

  * NII: ₹1,167 Cr ↑11% YoY | ↑2% QoQ

  * PPOP: ₹1,078 Cr ↑15% YoY | ↑1% QoQ

  * Provisions: -₹44 Cr vs -₹17 Cr (YoY) | ₹0 Cr (QoQ)

  * GNPA: 0.7% vs 1.2% (YoY), improvement of 50 bps

  * EPS: ₹4.55

  VARROC ENGINEERING Q2 FY27 Results:

  * Net Profit: ₹33 Cr ↓47% YoY | ↓57% QoQ

  * Revenue: ₹2,948 Cr ↑34% YoY | ↑12% QoQ

  * EBITDA: ₹257 Cr ↑27% YoY | ↑16% QoQ

  * EBITDA Margin: 8.7% vs 9.2% (YoY) ↓47 bps | 8.4% (QoQ) ↑30 bps

  * EPS: ₹2.15 ↓46% YoY | ↓58% QoQ

  * Other Income: ₹4 Cr

  IMFA: Q2 CONS NET PROFIT 1.5B RUPEES VS 975M (YOY)

  IMFA: Q2 EBITDA 2.34B RUPEES VS 1.4B (YOY); Q2 EBITDA MARGIN 24.3% VS 19.19% (YOY)

  SJS: Q2 CONS NET PROFIT 580M RUPEES VS 432.7M (YOY)

  SJS: Q2 EBITDA 834M RUPEES VS 683.6M (YOY); Q2 EBITDA MARGIN 29.5% VS 28.28% (YOY)

  SJS: Q2 REVENUE 2.8B RUPEES VS 2.42B (YOY)

  ALEMBIC PHARMA 2Q REV. 26B RUPEES, EST. 22.86B RUPEES

  ALEMBIC PHARMA 2Q NET INCOME 3.35B RUPEES, EST. 2.2B RUPEES

  BALRAMCHIN: Q2 CONS NET PROFIT 960M RUPEES VS 539M (YOY)

  BALRAMCHIN: Q2 EBITDA 1.7B RUPEES VS 1.20B (YOY); Q2 EBITDA MARGIN 9.14% VS 7.21% (YOY)

  BALRAMCHIN: Q2 REVENUE 18B RUPEES VS 16B (YOY)

  Parag Milk - Quick Key takeaways

  Paneer capacity expansion from 20 to 80 metric tonnes per day at INR 100 Cr investment expected to be commissioned by June 2025.

  Cheese capacity expansion from 60 to 120 metric tonnes per day at INR 105 Cr investment targeted for completion in FY28.

  Board has approved amalgamation of Bhagyalaxmi Dairy Farms with the company, subject to requisite approvals.

  Raw milk output is expected to grow by only 4% this year on account of weather conditions and higher product costs.

  Overall ASP (advertising and sales promotion) spend for the year is expected to be range-bound

  MAPMYINDIA: Q2 CONS NET PROFIT 352M RUPEES VS 185M (YOY)

  MAPMYINDIA: Q2 EBITDA 450M RUPEES VS 281M (YOY); Q2 EBITDA MARGIN 34.14% VS 24.72% (YOY)

  MAPMYINDIA: Q2 REVENUE 1.3B RUPEES VS 1.1B (YOY)

  APOLLOHOSP: Q2 CONS NET PROFIT 6.3B RUPEES VS 4.77B (YOY); EST 6.3B

  APOLLOHOSP: Q2 REVENUE 76.15B RUPEES VS 62B (YOY)

  APOLLOHOSP: Q2 EBITDA 11.9B RUPEES VS 9.4B (YOY); Q2 EBITDA MARGIN 15.64% VS 14.93% (YOY)

  BALKRISIND: Q2 CONS NET PROFIT 2.93B RUPEES VS 2.7B (YOY)

  BALKRISIND: Q2 EBITDA 6.33B RUPEES VS 5.12B (YOY); Q2 EBITDA MARGIN 18.24% VS 21.39% (YOY)

  BALKRISIND: Q2 REVENUE 34.72B RUPEES VS 23.9B (YOY)

  AUROBINDO PHARMA 1Q REV. 102.63B RUPEES, EST. 108.14B RUPEES

  AUROBINDO PHARMA 1Q OTHER INCOME 1.68B RUPEES

  AUROBINDO PHARMA 1Q TOTAL COSTS 87.41B RUPEES

  AUROBINDO PHARMA 1Q EMPLOYEE BENEFITS EXPENSES 16.59B RUPEES

  AUROBINDO PHARMA 2Q NET INCOME 11.3B RUPEES, EST. 11.32B RUPEES

• November 5, 2026 07:11

  Bullish momentum to sustain for Indian stocks on global rally

  Bullish momentum to sustain for Indian stocks on global rally

  Indian stocks likely to sustain bullish momentum amid positive global cues, FPI returns, and upcoming US/corporate results.

• November 5, 2026 07:03

  Stocks in focus, Nov 5: Alembic Pharma, Northern Arc, V2 Retail, Cupid, NALCO, Bright Outdoor, Som Distilleries, Manipal Health

  Stocks in focus, Nov 5: Alembic Pharma, Northern Arc, V2 Retail, Cupid, NALCO, Bright Outdoor, Som Distilleries, Manipal Health

  Market roundup: diverse corporate moves include Alembic-DifGen collaboration, Northern Arc’s ₹400cr fund close, V2-Cupid retail pact, NALCO’s smelter expansion, Bright Outdoor listing, Som Carlsberg extension, and Manipal Health land lease for a new hospital.

• November 5, 2026 06:49

  Today's stock recommendation: Usha Martin (₹486) – BUY

  Stock to buy today: Usha Martin (₹486) – BUY

  We expect the stock to sustain above ₹466 itself. Usha Martin share price can rise to ₹550 in the coming weeks. Traders can buy Usha Martin shares now at ₹486.

Published on November 5, 2026

THIS AD SUPPORTS OUR JOURNALISM. SUBSCRIBE FOR MINIMAL ADS. THIS AD SUPPORTS OUR JOURNALISM. SUBSCRIBE FOR MINIMAL ADS. THIS AD SUPPORTS OUR JOURNALISM. SUBSCRIBE FOR MINIMAL ADS.Sign into Unlock benefits!

• Access 10 free stories per month
• Get notified by email for early preview to new features, discounts & offers